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Introduction 
Hearing loss compounded by speech delay is one of the frequent and regular problems faced 
in the present day paediatric otorhinolaryngology clinics. The prevalence of hearing loss 
globally accounts for nearly 9% of the children according to recent estimates by the WHO 
and this represents a serious handicap to the society and the nation.(1) According to Indian 
statistics, it is found that the incidence of hearing impairment is 8 per 1000. Children under 
10 years of age account for nearly 5.4% of disabling deafness. The prevalence among urban 
children accounts for 1.2 % when compared to the rural side, 5.4%.(2) Thus it is considered 
the most prevalent impairment worldwide. 
Hearing impairment is the principal cause of disease burden in children and it proves to be a 
serious obstacle to their optimal growth and development. Besides being an impediment to 
their education, language skills and speech acquisition, these children gradually become 
disabled in multiple spheres of development including social, emotional, cognitive and 
personality traits, if left undiagnosed and untreated. This promising age group of the 
community who reflect a country‘s economic growth and development are thus handicapped 
from being responsible citizens and need special attention.  
Hearing development in children is seen to be a continuous process. Auditory system is fairly 
complete and functional at birth though the neural connections and the myelinations undergo 
refinement throughout childhood and adolescence, sometimes till 15 to 20 years of age. This 
plays a role in not just auditory perception, but in auditory speech perception. It is clear that 
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experience in the form of communicative interactions contribute significantly to speech and 
language development which becomes a functional need for the developing child.(3)  
The concept of auditory linked language acquisition becomes unique in humans. 
Neuropsychological studies claim that the brain which is developing is ‗plastic‘. This implies 
that the developing neural system is capable of adapting and reorganizing to various insults 
which the mature brain cannot. The detrimental consequence is that it has only a transient 
capacity to plastic reorganization which can be recruited in the wake of injury. The central 
role of neural plasticity thus reflects the need to pick up any hearing or speech delay at the 
earliest as the capacity for reorganization and shaping becomes limited in the postnatal 
period. The age at which hearing loss is picked up is also important as earlier diagnosis 
amounts to the best possible rehabilitation. 
While there is a wide range of tests which add to the diagnostic armamentarium, some of 
these tests warrant patient sedation for effective test recordings. Auditory Brainstem Evoked 
Response Audiometry (ABR) is one such diagnostic test to assess the brainstem responses to 
auditory stimuli thereby reflecting the integrity of the auditory pathway and its central 
connections. It has emerged out as being the standard test for hearing assessment in children 
undoubtedly. As it records the brainstem responses to simple auditory stimuli, it is important 
that the child remains immobile during the procedure to avoid any movement artefacts or 
false recordings. As children are poor candidates for the same, the need for paediatric 
procedural sedation becomes mandatory.  
Paediatric procedural sedation in the recent times, in the correct setting and in the hands of 
the adequately trained personnel has emerged as an elegant tool in the rescue of many 
3 
 
difficult diagnostic tests done as office-procedures. Many medications have been tried out for 
the same including a vast group of Opioids, Barbiturates, induction sedative - hypnotics and 
chloral hydrate. 
The various drugs used in the paediatric procedural sedation are not without their own merits 
and drawbacks. The onset and nature of sedation, the safety profile of these medications are a 
cause for concern. Besides, the failed efficacy of these medications in the ‗difficult-to-sedate‘ 
children like the developmental delayed ones, the hyper-active group lead to further concern. 
Chloral hydrate is one of the earliest known sedative. In view of its sedative and hypnotic 
potential, it remained attractive for many years for paediatric procedural sedation although its 
use came to a standstill in the mid 1990‘s due to its narrow margin of safety. Later various 
other sedatives were researched into. In the recent times, the Benzodiazepines have attained 
popularity for procedural sedation in view of their rapid onset of action and shorter recovery 
rates besides a wide range of margin of safety. Midazolam is one of the benzodiazepines with 
enticing pharmacokinetics and safety profile besides multiple routes of administration. The 
nasal mode of administration in the form of spray has its own advantages and shows patient 
friendly profiles. The clinical application of intranasal Midazolam has been studied in 
various medical fields.  
In our setting, it was found that nearly 20 % of the children who get referred for ABR are 
cancelled due to un co-operative behaviour or failed sedation with current protocol which 
entails syrup Triclofos (chloral hydrate) for paediatric sedation. Midazolam nasal spray has 
been used in a number of fields for paediatric sedation and as there was a need for an 
alternative drug in our setting, a pilot study was undertaken using intranasal Midazolam on 
4 
 
children undergoing ABR after parental consent and following favourable outcomes, the 
study protocol was designed 
In this study, we propose to study the efficacy and safety profile of Midazolam nasal spray 
for paediatric procedural sedation for Auditory Brainstem evoked Response audiometry and 
compare it with the standard drug used for ABR, syrup Chloral hydrate. 
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Aim & Objectives 
Aim 
The aim of the study was to evaluate the efficacy and safety of intranasal Midazolam 
compared to syrup Chloral hydrate for procedural sedation in children undergoing Auditory 
Brainstem Response Audiometry (ABR).  
Objectives: 
The primary objective of the study was to evaluate  
1. Safety,  in terms of  
 Heart rate  
 Respiratory rate 
 Oxygen saturation 
2. Efficacy,  in terms of  
 Level of consciousness (sleep and movement) 
 Successful completion of the procedure 
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The secondary objectives are to measure 
 Time for parental separation  
 Nature of parental separation  
 Time taken for onset of sedation  
 Duration of procedure  
 Time taken for recovery  
 Post recovery behaviour  
 Acceptance by parents  
 Audiologists satisfaction 
 Number of attempts 
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Review of literature 
1. Anatomy of hearing: 
Hearing is one of the four special senses humans are gifted with besides vision, olfaction and 
taste.  Studies say, we humans hear the way we do because of at least three major forces.(4) 
The first is phylogeny, the evolutionary changes in the auditory system since its beginnings. 
The middle ear of mammals is unique, in that, it is simply not an ‗improved‘ single-ossicle 
middle ear.(5) Another is embryology, the development of the system in each individual 
before birth.(6) Finally, there is the biologically determined auditory mechanism we are born 
with and our interaction with the environment in early postnatal life.(7) An insult in any of 
the stages of development significantly impairs the functional outcome. The complex 
network of hearing with diverse mechanisms thus begins very early in life.   
The perception of hearing requires a complex series of structures and can be viewed briefly 
as those comprising peripheral auditory structures and central auditory connections. External 
ear, middle ear and the inner ear comprises the peripheral hearing structures that collect the 
sound, transforms, transduces and converts it into electrical stimuli that can be interpreted by 
the human brain. (Fig. 1) 
Organization of the auditory system is based on the meticulous process of segregation of 
complex sounds into various bands of frequencies which starts at the point of the auditory 
sensory epithelium. Various specific frequencies get distributed along the cochlear tonotopic 
axis. This spatial layout of cochlear frequencies along the basilar membrane is repeated in 
other auditory areas of the brain. Tonotopy is a fundamental principle of organization of the 
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auditory system which arises from the cochlear mechanics and is evident as a linear 
arrangement of neurons in accordance with the characteristic or best frequency, i.e., that 
acoustic frequency to which a neuron is most sensitive.(8)  
 
Fig.1 Anatomy of the external, middle, and inner ear (Reprinted from Netter Anatomy 
Illustration collection, Elsevier Inc. All Rights Reserved). 
During development, physiological and structural specializations that are related to the 
tonotopic axis steadily evolve and expand over a prolonged time period. During early stages 
of auditory development, some aspects of tonotopy become evident, but mature frequency 
separation is characteristically not attained till hearing takes its onset.(9) 
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Fig.2: Auditory pathways and sound localization.  
The complexity of human auditory system is characterized by a remarkably specific spectral 
and temporal neural code inside the auditory brain stem which is an assembly of nuclei 
encircling the afferent and efferent auditory neural pathways. The central auditory 
connections are viewed as follows: (Fig. 3) 
In humans, the eighth cranial nerve, i.e., the vestibulocochlear nerve is seen to originate from 
4 separate nerve branches which are the saccular nerve, the superior vestibular nerve, the 
posterior ampullary nerve and the cochlear nerve. The cochlear nerve is formed within the 
spiral ganglion by the bipolar neurons whose central processes join the vestibular nerve 
inside the internal auditory meatus or porus acousticus. The cochlear nerve fibres take a 
spiral track and show a cochleotopic organization.(10) That is, the fibres which originate 
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from the basal cochlear turn are located external to the deeper fibres that originate from the 
apical cochlear turn.  
 
Fig.3: Auditory pathways and sound localization.  
The cochlear nerve and the vestibular nerve as they travel from the most peripheral end of the 
internal acoustic canal to the cerebello-pontine angle show a variable relationship. The two 
nerves take a 90 degrees rotation from the inner ear to the brainstem. The cochlear nerve is 
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antero-inferior inside the internal acoustic canal and enters the brainstem postero-lateral to 
the vestibular nerve. The eighth cranial nerve divides into two separate branches and at the 
ponto-medullary junction, it enters the brainstem.  It is at the level of the rostral medulla, 
both branches enter the brainstem and are separated by cerebellar peduncle. The cochlear 
nerve fibres pass over the restiform body and enter from the ventromedial surface to reach 
the anteroventral cochlear nucleus. The vestibular fibres pass beneath the restiform body 
where they pierce the trapezoid body and advance dorsally into the brainstem.   
1.1 Cochlear nuclei: 
 
Fig.4:   Cochlear nuclei.  
The cochlear nuclei correspond to the foremost and obligatory relay station for all the 
afferent auditory nerve fibres. It is seen on either side at the ponto-medullary junction, lateral 
to the point where the eighth cranial nerve enters. This nuclei is divided into 2 major 
subdivisions which are the ventral (VCN) cochlear nuclei & dorsal (DCN) cochlear nuclei. 
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The VCN is further structurally sub classified into anteroventral (AVCN) and posteroventral 
(PVCN) cochlear nuclei. The AVCN again has 2 subdivisions: the anterior and the posterior 
divisions. Each of the subdivisions comprises of a distinct collection of cell types which are 
greatly diverse between species and obtain a comprehensive topographic representation of 
the auditory nerve. Based on the cell morphology, five neuronal classes are identified, which 
are - the bushy cells (spheric and globular), the multipolar, the pyramidal, the octopus and the 
granule cells. The AVCN consists of the spheric bushy cells in the anterior division and the 
globular bushy cells in the posterior division. The central region of the ventral cochlear 
nuclei is represented by the multipolar cells (stellate neurons). Octopus cells characterize the 
PVCN where the cells are oriented orthogonally to the incoming cochlear nerve fibres. These 
neurons are known to respond to repetitive acoustic stimuli. Pyramidal and granule cells 
compromise the DCN.  
The nerve fibres distributed throughout the cochlear nuclei show a distinct and a standard 
cochleotopic order. Every subdivision of the cochlear nuclei displays a fairly complete and 
comprehensive neural depiction of the entire frequency range of the cochlea. The axonal 
nerve fibres from the cochlear base project most dorsally, while those from the apex project 
ventrally in each one of the subdivisions.  
The axons of the 2
nd
 order neurons arising from the DCN (caudal medulla) shape into three 
principal bundles. They are the ventral acoustic stria (trapezoid body or VAS), the 
intermediate acoustic stria (IAS or stria of Helde) and the dorsal acoustic stria (DAS or stria 
of Monackow). The VAS begins from the spheric and globular bushy cells of the VCN and 
tracks medially and cranially across the medulla and reaches the LSO, the MSO, the MNTB 
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& the inferior colliculus. The IAS takes its origin primarily from the octopus cells 
comprising the PVCN and projects ipsilaterally, bilaterally, or contralaterally onto the 
trapezoid body into the ventral nucleus, besides projecting onto the lateral superior olive and 
the periolivary region. This forms the olivocochlear bundle. The DAS is primarily a crossed 
pathway through which the cells in the DCN project to the nuclei of the lateral lemniscus 
besides the central nucleus of the inferior colliculus.     
1.2  Superior olivary complex: 
The superior olivary complex is situated in the caudal pons directly and dorsal to the pontine 
gray. The large nuclear complex encompasses the lateral nucleus of the superior olive (LSO), 
the medial nucleus of the superior olive (MSO), the medial nucleus of Trapezoid body 
(MNTB) and the periolivary nuclei (PON). The MSO is characterized by bipolar neurons 
while the LSO by multipolar neurons. The MSO is innervated both ipsilateral and 
contralateral from the ventral cochlear nuclei through the VAS. The LSO receives ipsilateral 
inputs from the AVCN and PVCN via the trapezoid body. There is a topographic 
organization seen such that the dorsal and ventral PVCN project onto the extreme lateral limb 
and medial limb of the LSO. The tonotopic organization of the afferent cochlear nerve input 
to the LSO is maintained such that the axonal nerve fibres from the high-frequency regions 
terminate in the medial end while the lower-frequency area in the lateral limb. The contra 
lateral inputs arise from the caudal AVCN and rostral PVCN through the MNTB.  
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Fig.5: Superior Olivary complex.  
The MNTB takes its projections from both the ipsilateral PVCN and the contra lateral AVCN 
via specific calyx-type endings which surrounds the MNTB cell body partially. The PONs 
receives afferent input from the CN.  
The tonotopic organization is thus maintained in the superior olivary nuclei bilaterally and 
receives bilateral auditory inputs from the cochlear nuclei with lower-frequency of neurons in 
the MSO and high-frequency neurons in the LSO. Neurons from this nuclear complex are 
responsible for sound localization in acoustic space and are the first to receive binaural inputs 
in the entire auditory pathway. The distinct patterns of binaural convergence on MSO and 
LSO may play a key function in the inter-aural intensity and temporal disparities which 
underlie mechanisms for binaural spatial hearing. 
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Fig. 6: Sound Localization in the Superior olive.  
The fibres which ascend the superior olivary complex (SOC) reach the nuclei of the lateral 
lemniscus and the inferior colliculus through the lateral lemniscus. It also sends fibres which 
descend to the hair cells in the organ of Corti through the olivo-cochlear bundle (OCN), 
divided into medial and lateral parts, initially described by Rasmussen. The ipsilateral & 
contra lateral systems traverse peripherally such that the inferior division of the vestibular 
nerve joins the cochlear nerve at the vestibulo-cochlear anastomosis of Oort within the 
fundus of the internal acoustic meatus. These descending connections particularly the crossed 
fibres adjust cochlear sensitivity to the sound, probably by mediating the contractile 
properties of the outer hair cells. 
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1.3 Lateral Lemniscus: 
The lateral lemniscus forms the chief ascending pathway and is situated cranially in the 
vicinity of the lateral surface of the brainstem, connecting the cochlear nucleus and superior 
olivary nucleus with the inferior colliculus. The nuclei of lateral lemniscus show a tonotopic 
organization with low frequencies projected dorsally and high frequencies situated ventrally.  
The axons of the third-order neurons from the superior olivary complex (SOC) and nucleus 
of the trapezoid body rise up either side in the lateral lemniscus. A majority of these axons 
ascend in the contra lateral lemniscus and project to the nucleus of the lateral lemniscus at the 
level of the ponto-midbrain junction. The neurons in the nucleus of lateral lemniscus, further, 
project onto the inferior colliculus. 
1.4 Inferior Colliculus: 
The inferior colliculus comprises of bilateral mesencephalic structures and represent the 
primary relay station for all the auditory ascending pathways. It processes auditory 
information from the lower brainstem to the medial geniculate body and terminates onto the 
auditory cortex. The dorsal portion of the inferior colliculus takes projections from neurons 
which respond to low sound frequencies, while the ventral portion from those neurons that 
respond to high sound frequencies. This auditory information thus obtained is further 
processed and relayed by the inferior colliculus to the medial geniculate nucleus of the 
thalamus. There is a regular tonotopic organization seen such that the fibres are arranged in a 
low to high frequency order along the dorsal to ventral region with iso-frequency laminae 
congruent with the orientation of the dendritic laminae.  
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1.5 Medial Geniculate Nucleus: 
The medial geniculate nucleus of the thalamus is seated at the caudal aspect of the thalamus, 
proximal to the midbrain, intercalated between the fibres of the inferior colliculus and the 
auditory cortex. The axons of the neurons of the inferior colliculus transmit auditory signals 
to the medial geniculate body of the thalamus which is tonotopically arranged and relays 
precise information about the frequency, intensity and binaural sound properties. These 
neurons through their axons, further, project to the primary auditory cortex 
1.6. Primary auditory Cortex: 
In humans, the cytoarchitectural properties, the fibre connections and the physiologic 
properties divide the auditory cortex into primary auditory cortex which is situated in the 
transverse temporal gyri (of Heschl) of the medial aspect of the superior temporal gyrus and 
associated auditory regions which collect auditory and other sensory inputs. Brodmann‘s 
areas 41 and 42 are known the primary auditory area, A-1 region and receive projections 
from the medial geniculate nucleus (geniculotemporal fibres or auditory radiations). The 
tonotopic organization which is observed in the auditory relay nuclei is well observed in the 
auditory cortex. This cytoarchitecture resembles closely the other primary cortical sensory 
areas. 
Brodmann‘s areas 22 and 52 are the auditory associated areas that connect the primary 
auditory cortex with the frontal and temporo-parietal regions which are concerned with 
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speech & language, somaesthetic and vision areas. One of the secondary auditory areas 
include Wernicke‘s area, essential for the spoken word interpretation. 
  
 
Fig. 7: Primary auditory cortex.  
The sound impulses as they pass through the various levels at brainstem and the auditory 
cortex can be shown to elicit waveforms that can be graphically represented, thus helping in 
the diagnosis of the anatomical site of lesion.  
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2. Physiology of hearing and speech: 
 Hearing is a multifaceted special sense that co-exists with the other special senses. The 
concept of hearing has been viewed since 1700s. Philosophers debate if a falling tree made 
sound if there was no one nearby to hear the sound. Physicists viewed sound as a science of 
acoustics while Psychologists felt it as a personal quality of sensory perception. It was 
conceptualized that the human reaction to sound was hearing.  
Auditory perception is defined as the interpretation of sensory evidence that is derived from 
sound, in terms of the object and events that caused the sound. It involves the use not only of 
sensory evidence, but also of contextual evidence, prior knowledge, memory, attention and 
processing skills.(3) Auditory speech perception is unique to humans, as the events to be 
perceived are those of language.  
Hearing develops in-utero such that the first response to hearing has been recorded at 20-25 
weeks of gestation. The auditory system is complete and functional at birth but myelinations 
continue for several years after birth in the auditory neural pathways. Human baby at birth is 
knowledged with pre-existent language specialized neural structures. These neurons only 
await acoustic experience with symbol based communication system. This explains how 
important it is for a child to attain auditory development and maturity in order to co-ordinate 
the co-existing special senses. This auditory linked language acquisition is unique to humans 
and is related to early maturational periods in the infant‘s life. This underlies crucial periods 
for biologic functions of humans.  
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Human developmental neuropsychological studies claim that the brain which develops is 
‗plastic‘. That is, the immature brain has unique characteristics to reorganize and to re-shape 
its various neural connections which the mature brain cannot. This is why, the developing or 
the immature brain is much less susceptible to the detrimental damages than the more mature 
brain. Normal brain follows a maturational set pattern including both input from the 
environment and the genetic factors. Any unfavourable insult which perturbs this 
maturational process is circumvented effectively as the entire system responds neatly thus 
preventing any functional deficit. It is evident from studies that focal brain insult suffered 
early in life is far better than the affective and cognitive impairments manifested due to 
insults suffered in later life. These less devastating and differential outcomes following early 
insults are ascribed to the developing brain‘s ability for neural plasticity. This exceptional 
capability for reorganization, however, declines gradually with maturation. 
Lenneberg in 1967 put forward the theory, the neurons and their connections which mediate 
language and other higher cognitive functions pursue a maturational outline during 
development. There are genetically pre-specified different brain regions that become eligible 
for particular cognitive functions. Under appropriate maturational calendar, these qualified 
regions become devoted to pre-designated functions. In most adults, functioning normally, 
the brain showcases such a maturational profile of organization. Yet, if the developing or the 
immature neural substrate confronts any insult, the brain displays alternate reorganization 
patterns. This neural plasticity happens as the maturing brain has not yet devoted its entire 
subset of resources. Thus, one region of the brain if faced with injury, there are sufficient 
neural structures and connections that are available to sustain the developing functions. 
However, there is decline in the brain plasticity as it develops such that it shows a gradual 
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dedication of neural resources to well defined functions maturationally with a parallel loss in 
the system‘s flexibility and capacity to reorganize .  
Various authors have put forward the upper age limit for linguistic recovery following early 
insult. Lenneberg in 1967 was far too optimistic in postulating the upper age limits at about 
12. Krashen ad colleagues in 1973 concluded that the brain plasticity does not happen after 
about age 5. The work in 1978, by Wood and Carey brought the limits of recovery even 
lesser than the first year of age. The human hearing frequency is known to range between 20 
to 20,000 Hz. The output range of pitch of human speech encompasses broad range of 
frequencies from 500-3500 Hz which is nearly identical to the optimal hearing frequency 
sensitivity. 
Sound is collected via the pinna, transmitted through the external auditory canal and strikes 
the tympanic membrane which has a larger surface area than the stapes footplate. This area 
mismatch provides an impedance matching between the sound wave in environmental air and 
inner ear fluids. Compression and rarefaction of inner ear fluids are further enhanced by the 
lever action of the ossicles - Malleus and Incus. Displacement of the inner ear fluids results 
in depolarization of the organ of Corti in the hair cells. The base of the depolarized hair cell 
then activates the cochlear division of the vestibulo-cochlear nerve, the eighth cranial nerve 
via synaptic transmission. The action potential thus generated ultimately gets processed via 
the auditory brainstem and cortex in the perception of sound. This way, sound is perceived as 
hearing. It is in the auditory cortex that the initial auditory signal once processed, the speech 
sounds are further processed to extract the auditory cues and phonetic information.  
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3. Effects of hearing impairment: 
The impact of hearing impairment is seen in many domains of development in a growing 
child right from the child‘s speech, language, cognition, psycho-educational and social-
emotional competence. The degree and type of hearing impairment and the age at diagnosis 
play an important role.  
A. Functional impact: 
One of the principal impacts of impaired hearing is on the individual‘s skill to communicate 
effectively with others. Language learning is key to the development of any child. As 
discussed earlier, the language physiology depends on the hearing maturity and thus spoken 
language development is often delayed in hearing impaired children. The receptive and the 
expressive communication skills of these children show a significant delay.  
In 1978, Skinner, documented a number of detrimental ‗acoustic liabilities‘ to a child‘s 
language learning when hearing loss exists like the following, 
 There is lack of constancy of auditory clues when auditory signal fluctuates and there 
is an inconsistent categorization of speech sounds.  
 There is confusion of acoustic parameters with rapid speech. 
 There is confusion in segmentation and prosody - the child with hearing loss may 
miss linguistic boundaries like plurals, tenses, intonation and stress patterns. These 
interpretations are requisite for meaningful interpretation of speech.  
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 Breakdown of early ability to speech sounds - an infant begins to learn to discriminate 
speech sounds almost immediately after birth. Learning can be impeded if the sounds of 
speech are not perceived early in life.  
 Breakdown in early perception of meanings - during ordinary speech, the normal 
listener often misses some unstressed or elided words or sounds but is often able to fill in by 
understanding the context of the message. However, a hearing impaired child tends to miss 
many of these soft or inaudible sounds and there is confusion in word naming, word order, 
difficulty in developing classes of objects and misunderstanding of multiple meanings.  
 There is faulty abstraction of grammatical rules.  
 Subtle stress pattern is missed - the emotional intent of speech, its rhythm, intonation 
is confused, another condition that impairs learning of speech and language.  
These various parameters can handicap a child at different levels of hearing loss. This 
explains that one of the profound impacts of deafness is in the spoken language.  
A mild hearing impaired child may miss out on the consonants, less intense speech sounds, 
voiceless stops and fricatives that only louder voiced speech is heard. This has a significant 
effect on language learning, communication and education. Most of the conventional speech 
sounds is missed in moderate hearing loss that these children have a significantly lower 
numbers of phrases and words understood besides gestures and strangers find it difficult to 
understand the speech of these children. A child with severe and profound hearing loss is 
severely handicapped that language and speech do not occur spontaneously.  
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Hearing loss thus affects speech and impaired speech encroaches onto the language learning 
which significantly hampers the communication skills. Be it understanding their own voices 
or the others around them, these children show a different pathway with difficulty in all areas 
of communications development.  
The academic development of a child at various levels suffers a delay in the hearing and 
speech impaired children. Pre-school children suffer learning the language while in school-
aged children, it manifests as poor performances in language - based tests, class tests, class 
participation, volunteering activities, verbal communication and interaction with peers and 
teachers. The grasping capabilities and the verbal memory get hampered. All these 
difficulties put together leads to poor academic achievement, often leading to school failure, 
especially in the lower grades. A child, until it reads newer information, most of classroom 
learning is through auditory learning.  
B. Emotional impact:  
Children especially are a source of joy to the parents and the family. Any insult to children 
incurs a heavy emotional burden on the part of the parents and the caregivers. The speech 
and hearing impaired children need special attention and additional care. Besides ensuring 
the best of care, parents themselves suffer an emotional letdown and stressful period many a 
time, and become emotionally labile. Several studies point out the lack of communication 
capabilities and experiences with hearing-impaired children on the part of many 
investigators. Besides, delays have been noted for the development of social maturity among 
hearing-impaired children and the parents' descriptions many a time, may reflect their own 
worries, if not, the emotional and behavioural functioning of the child.(11)  
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C. Neuropsychiatric impact: 
The poor verbal communication skills results in introversion of these children and thus social 
isolation. These children as a result get underexposed to the worldly experiences and the 
repeated failures can lead to a long term impact by contributing to low self-esteem which 
itself may limit their opportunities and vocational choices. Increased incidences of 
behavioural problems have been reported to occur among the hearing impaired children. 
Behavioural problems may take up outward appearances such as aggression, hyperactivity, 
temper-tantrums, while from within, these may equate to or reflect from depression, anxiety, 
social seclusion, learning disabilities, negative self-image and many. Self- expression 
becomes difficult for many of these children and as a result become more inner-focused.  
The neuropsychiatric impact of hearing impairment on children has been investigated and has 
been found that these children pursue various diverse developmental pathways. The 
measurement of various psychiatric symptoms is quite compromised as many of the 
evaluation procedures are highly verbal and were normalized for children with normal 
hearing. Accurate evaluation is thus hampered by the immature and undeveloped language 
displayed by many hearing-impaired children and by the hardships that may be faced in 
establishing rapport if the child does not comprehend the investigators verbal interactions. 
All these problems show that the prevalence of mental disorders among hearing-impaired 
children and adolescents shown in the literature differ from 15% to 60%.(11) It is also said 
that hearing impairment may be a pointer for brain insult in autism.(12) Various studies have 
explained that there is a higher degree of impulsivity exhibited by the hearing impaired 
children than their normal counterparts.(12) 
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D. Economic impact:  
The economic impact caused by the hearing impairment needs special mention. It causes a 
heavy economic burden on not just the individual and the family, but it has an impact on the 
society as well. The school failure rates among the hearing impaired children is not low and 
the retention rate among these children and the cost of retaining such a student adds to the 
economic burden to the educational systems. The lifetime educational costs that these 
children incur add to the significant crisis. Once out of their schools, the jobs that are held by 
these children often carry a lesser pay.  
 Children who are hearing impaired or speech delayed warrant multiple clinical visits right 
from the time of diagnosis or even in-utero. The multiple diagnostic tests to establish the 
diagnosis or to rule out one are not without expensive nature these days. Many a time, these 
children may need to be given repeated appointments for the various procedures especially 
those requiring sedation thus adding to the economic burden on the family. The 
interventional procedures when explained to the parents are not without complications and 
the parents may need to be ready to face them. Parents with ‗precious children‘ especially 
may not have an option and many a time do not think otherwise, rather try out the various 
diagnostic and interventional tests, all to bring out the best of the treatment outcome for their 
children. In the current day world, when both the parents are employed, may serve additional 
impedance to the number of hospital visits and planning schedules.   
As the parents are involved in the health care of these children, their work schedule may get 
disturbed which reflects on their pay pattern and ultimately the family income. The entire 
schedule thus significantly adds to the economic crisis to the family. Not to forget is the 
27 
 
mental trauma the couple and the family go through, many a time needing to manage the 
family member as well besides the child who is impaired. This may again intensify the 
medical costs and add to the economic crisis in the family. It needs to be mentioned that not 
just the family which suffers, but, has an indirect effect on the society as well. The regular 
work-offs by the parents significantly adds to the decrease in productivity with higher 
unemployment and lower wages which serves as an impediment for the economic growth of 
the society.  
4. Global burden and statistics: 
Hearing impairment is the most common but worrisome disability in today‘s industrialized 
world. According to the American Speech language and Hearing Association, hearing 
impairment can be classified and defined as following:(13)(14) 
Slight impairment: is defined as when pure - tone hearing threshold level, unaided, for the 
better ear of 16 - 25 decibels (dB), taken average of the (HL) hearing threshold levels for the 
frequencies - 500Hz, 1kHz and 2kHz 
Mild impairment: is defined as when pure - tone hearing threshold level, unaided, for the 
better ear of 26 - 40 decibels (dB), taken average of the (HL) hearing threshold levels for the 
frequencies - 500Hz, 1kHz and 2kHz 
Moderate impairment: is defined as when pure - tone hearing threshold level, unaided, for the 
better ear of 41 - 55 decibels (dB), taken average of the (HL) hearing threshold levels for the 
frequencies - 500Hz, 1kHz and 2kHz 
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Moderately severe impairment: is defined as when pure - tone hearing threshold level, 
unaided, for the better ear of 56 - 70 decibels (dB), taken average of the (HL) hearing 
threshold levels for the frequencies - 500Hz, 1kHz and 2kHz 
Severe impairment: is defined as when pure - tone hearing threshold level, unaided, for the 
better ear of 71 - 90 decibels (dB), taken average of the (HL) hearing threshold levels for the 
frequencies - 500Hz, 1kHz and 2kHz 
Profound impairment: is defined as when pure - tone hearing threshold level, unaided, for the 
better ear of 91 decibels (dB) or greater, taken average of the (HL) hearing threshold levels 
for the frequencies - 500Hz, 1 kHz and 2 kHz 
Hearing loss is viewed as a hidden disability, according to the World Health Organization. 
As per the study by the Global Burden of Disease in 2000 that was reported by the World 
Health Organization which was published in the WHO World Health Report in 2001, 
childhood and adult onset deafness was calculated to affect around 250 million people 
worldwide. According to International studies, hearing impairment was identified when an 
average hearing level of >= 35 decibels was noted in the better ear. Estimating the prevalence 
globally, in 2008, it was found nearly 1.4% children aged 5-14 years were hearing impaired, 
while for females >15 years of age, it was 9.4% and was 12.2% for males in the same age 
group.(1)(11) 
Based on 42 population-based studies, the WHO, in 2012 released newer estimates on the 
degree and enormity of disabling hearing loss. It defined disabling hearing loss when in 
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adults (15 years or older), a loss > 40 dB in the better hearing ear and more than 30 dB in the 
better hearing ear in the paediatric age group (0 to 14 years). It has been projected that nearly 
360 million people accounting for nearly 5.3% of the entire world‘s population suffer 
disabling hearing loss with 9% of these being children. The prevalence showed an unequal 
distribution with the greatest seen among the developing countries in Asia Pacific, South 
Asia and Sub-Saharan Africa. The prevalence decreased exponentially as the Gross National 
Income per capita increased. Also, the prevalence decreased linearly as parents literacy rate 
increased.  
In the US, the average incidence of hearing loss was 1.1 per 1000 infants. The prevalence of 
mild hearing impairment or worse (>20dB) was 3.1 percent with the low income households 
demonstrating a higher prevalence of hearing loss compared to the higher income levels.(15) 
According to Indian statistics, the National Sample Survey Organization (NSSO), 
Government of India, 1991 reported that among children in the age group 0 to 14 years, 2.7% 
in rural India and 3.0% in the urban side are known to have hearing impairment. The same 
survey showed the statistics as 8.3% and 8.9% in rural and urban side respectively for 
children with speech disability. The incidence of hearing impairment in India amounts to 8 
per 1000 with 4 out of every 1000 children suffering severe to profound bilateral congenital 
hearing impairment.(16)(17) A recent survey conducted in one of the Indian states showed an 
overall hearing impairment in the rural sector to be 15.14% as opposed to the urban side, 
5.9%. Children <10 years accounted for 5.4% for disabling deafness. The prevalence in 
urban children was 1.2 % when compared to the rural side 5.4%.(2) This underscores the 
need for early diagnosis and appropriate management. 
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5. Diagnostic audiology tests: 
Hearing loss thus needs to be diagnosed early in life for adequate, appropriate and timely 
rehabilitation. There is a battery of objective diagnostic audiology tests done as office 
procedures to evaluate these condition.(18)  
Behavioural test methods are available which form critical components of the comprehensive 
audiometric assessment battery for infants. These test methods must be developmentally 
appropriate for appropriate age group. There are two general categories of test approaches 
that are used in paediatric behavioural audiometric assessment.  
1. Unconditioned test procedures: 
 Behaviour observation audiometry 
2. Conditioned response procedures: 
 Visual reinforcement audiometry 
 Conditioned orienting response 
 Play audiometry  
The Joint Committee of Infant Hearing (JCIH) encourages early detection and timely 
intervention of children with hearing loss with a goal of maximizing linguistic competence 
and literacy development besides functional intelligence. This is achieved by Universal 
neonatal hearing screening when children are discharged from hospital or within their first 
31 
 
month of life. Children should be referred for further expert opinion, should screen tests 
report ‗positive‘. A battery of tests is undertaken to confirm the diagnosis, this should be 
made by the third month of life and therapy should be started by the sixth month of life. 
Thus, this has significantly added to the work load of the audiologists and the speech 
therapists. As children cannot be expected to respond reliably to subjective hearing tests, the 
significance of the objective tests become underlined.(19)  
The auditory electrical potentials provide the most accurate, convenient and objective method 
to assess the functioning and performance of the auditory system especially in children when 
behavioural audiometry does not help. These auditory electrical potentials are known to 
originate from various levels of the ascending auditory neural pathways at precise time 
intervals following the sound stimulus. Studies on electrophysiological work on organ of 
hearing was initiated since the experimental research of Luigi Galvani‘s discovery of 
electrical activity at locating the cortical hearing centre.(20) The importance of electrical 
potentials from cochlea and auditory nerve fibres was studied by Wever & Bray in addition 
to Ruben‘s team of Baltimore besides leading studies done by Hallowel Davis who is known 
as the ―father of ERA studies‘‘ which is  Electric Response Audiometry. Auditory Brainstem 
Evoked Response (ABR) is one such objective electrophysiological test that assesses the 
brainstem response to simple auditory stimuli.(21)(22) 
6. Auditory Brainstem Evoked Response audiometry (ABR) : 
Auditory brainstem evoked response audiometry is an effective and a non-invasive method of 
evaluating the auditory pathway from the peripheral end organ through the brainstem. 
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Besides, evaluating for the structural lesions, it helps in determining the auditory thresholds. 
(23) 
6.1. History and origin: 
It was Sohmer and Feinmesser in 1967 who were the first to publish reports on ABR. Later, 
it was Jewett and Williston in 1971 who clearly interpreted and described the waves as those 
arising from the brainstem.(24) Selters & Brackman in 1977 came up with breakthrough 
findings on inter-peak latencies in those tumours that were greater than 1 cm being 
prolonged. Hecox & Galambos in 1974 explained that ABR could be used for threshold 
estimation in both infants and adults.(25) Starr & Achor in 1975 were the first to describe the 
effects of central nervous system pathology in the brainstem on ABR. Since then, ABR has 
become an effective and an invaluable tool with a wide array of clinical applications 
including universal newborn hearing screening, retro-cochlear pathology screening, 
frequency-specific estimation of auditory sensitivity, ICU and intra-operative monitoring 
especially in neurosurgical cases.  
6.2. Other names : 
It has been called as Brainstem Auditory Evoked Response (BAER), Auditory Brainstem 
evoked Response audiometry (ABR), Brainstem Evoked Response Audiometry (BERA), 
Brainstem Auditory Evoked response Potential (BAEP). 
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6.3. Clinical applications:  
American academy of Otolaryngology – head and neck surgery has suggested ABR in 
various clinical indications. It can be used as a screening tool for hearing, besides serving as 
a tool in the diagnostic assessment of the degree of hearing loss in infants and in those 
individuals in whom a conventional hearing test cannot be performed. It is also used in the 
operating theatre to monitor the eighth nerve function while surgery.  
6.4. Principle: 
ABR monitors the electrical activity of the acoustic nerve and the brainstem nuclei. It 
consists of evoked electrical potentials produced by the synchronous activity of the neuronal 
populations in the brainstem, the neural responses of which are collectively measured 
passively and objectively. It thus provides a tremendous means to measure auditory threshold 
in a clinical setting.  
Studies on ABR used simple click stimuli or burst tones, to start with. Although these have 
been helpful in determining the basic responses, they appear to be poor estimation of the 
behaviourally appropriate sounds that are encountered normally outside the laboratory. There 
is a plethora of complex stimuli that has now been used to assess how the spectral and 
temporal qualities of sounds are preserved in the ABR. In 1980, Greenberg was one of the 
earliest to adopt complex stimuli to record ABRs. Young& Sachs in 1979, showed that 
speech formants are conserved in the discharge pattern of the eighth nerve, Greenberg in 
1980 noted that speech-specific information / vowel formants is also programmed in the 
ABR faithfully. 
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6.5. Waveforms in ABR: 
The surface electrodes are positioned at the vertex of the scalp and the ear lobes and the 
waveform response are measured and graphically represented with amplitude of the signal in 
micro-voltage averaged and charted against time in millisecond. The wave form peaks are 
marked using roman numerals I –VII, each of which are separated in latency by nearly one 
millisecond. Normally, these waveforms occur within a 10 millisecond time period following 
a click stimulus at high intensities with 70-90 dB normal hearing level. These waveforms are 
produced as the signal travels along the auditory pathway representing successively higher 
order of neuron activity at specific time intervals.(26) Various levels correspond to the 
specific location along the pathway. The criteria are based on the individual peak latencies 
and inter-peak latencies.(27) Individual latencies of waves I, III and V, amplitude ratio of 
wave V to wave I, inter-peak latencies of  I-III, III-V and I-V are the common factors 
evaluated for evaluating clinically relevant abnormalities (28). 
 
Fig. 8: Waveforms in ABR.  
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Specific representations of the various waveforms: 
Waveform I: The ABR wave I corresponds to the action potential from the distal portion of 
auditory nerve. This represents the afferent activity or the first order neuronal response from 
the eighth nerve as they exit the cochlea and enters the IAC. 
Waveform II:  The ABR wave II is produced by the proximal eighth nerve as it makes its 
entry into the brain stem. 
Waveform III: originates beyond the eighth nerve from the second-order neuronal activity in 
or near the cochlear nucleus. Some studies suggest the response to be contributed in addition, 
from the caudal portion of the auditory pons. It is to be noted that the nearly one lakh neurons 
which comprises the cochlear nucleus is mostly innervated by eighth cranial nerve fibres. 
Waveform IV:  is seen mostly to share the same peak with wave V. It is believed to originate 
from the third-order neurons mostly situated in the superior olivary complex, in the pons, 
with additional contributions from the cochlear nuclei and the nucleus of lateral lemniscus. 
Waveform V: is the wave analyzed most often in the clinical setting. It likely represents the 
activity arising from multiple auditory structures. Though some debate exists on the exact 
generation of wave V, it is believed that it originates from the vicinity of the inferior 
colliculus along with some additional contribution from the second-order neuron activity. 
The inferior colliculus is known for its complex structure, with more than 99% of the axons 
from lower auditory brainstem regions traversing through the lateral lemniscus to the inferior 
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colliculus. Due to its stability and consistency, the waveform V is prominent and considered 
important in the interpretation of the auditory threshold sensitivity. 
It has been found that the polarity of the stimulus influences latency, waveform and 
amplitude of the response curves. A bifid wave form with splitting of the wave form peaks 
IV and V in separate peaks has been noted following rarefaction stimulation while the 
condensation stimulus produces a single-peaked contribution. The splitting of the wave 
complex IV and V may be traced to mechanical processing in the cochlea.(29) 
Waveforms VI and VII: are generated from the medial geniculate body of the Thalamus, but 
the precise site of generation is uncertain. 
Thus various waveforms can be obtained pertaining to the specific pathology and the 
morphology along with the above parameters help in localizing a lesion or obtaining the 
threshold of hearing.  
6.6. Effect of aging on ABR responses (infants and children Vs adults): 
Aging shows a significant effect on the wave form responses. The various parameters 
undergo distinct maturational transformations in early life affecting both the peripheral and 
central auditory structure.(30) There is essentially an exponential growth with equal 
maturation rate for each auditory station.(31) The changes are evident even in the first hours 
after birth.(32) The auditory nerve maturation is seen to occur at a rate considerably faster 
than that for more central parts of the nervous system. The waveform morphology differs in 
several important ways for infants and children when compared to an adult. In infants with 
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normal development, peak latencies and waveform morphology approach adult values by 
around age, 18 to 24 months. Nevertheless, prolonged latencies may continue to persist in 
children beyond this age range due to sensory and conductive involvement, developmental 
delays, particularly at lower intensity levels. Thus, while assessing infants and young 
children for threshold predictions, it is essential to extend the recording or analysis window 
beyond the 10 ms period classically used with adults. 
In preterm infants, a typical bow tie pattern is seen preceding peak III. This appears 
approximately 0.1 millisecond before the ipsilateral peak III and it appears to be the earliest 
characteristic of the developing waveform morphology in preterm infants.(33) This implies 
why there should be postponement of neonatal hearing screening until after 34 weeks, as the 
waveform characteristics in ABR will improve with age. Beyond this period, prematurity 
does not appear to have any effect on the maturation rate or on the time to maturity of the 
brainstem auditory potentials.(31) The most reliable waves during the first month of life are 
waves I, III, V.(34) There is a substantial reduction in amplitudes of all major ABR peaks 
with considerable latency shifts limited to wave forms I and III, but no influence on I-V 
inter-peak latencies even at high click rates. This observed absolute latency shifts in the 
responses can be ascribed to the changes in auditory nerve input with progressive 
myelinations of the auditory tract in infants.(35)  
6.7. Effect of anaesthesia on auditory brainstem responses: 
Animal studies have shown that anaesthesia is known to affect the various wave form 
responses. Under anaesthesia, the measurement accuracy of peak latencies, inter-peak 
latencies and the various thresholds decreases. Several anaesthetic agents like sevoflurane, 
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isoflurane, enflurane and temperature changes associated with undergoing anaesthesia are 
known to increase the conduction time. The wave form generated by the distal portion of 
VIII nerve, i.e., wave I is spared while there is an increase in central conduction time which 
results in delayed ABR absolute and interpeak latencies, e.g., III, V, I-III, III-V, I-V.(36) The 
agents studied and known are ketamine, xylazine. At physiological doses, hearing thresholds 
obtained with isoflurane were shown to be elevated across a broad frequency range by 
greater than 27 dB. On an average, isoflurane is found to dose-dependently reduce the 
amplitude and increase the latency of the ABR. These effects are typically seen when 
isoflurane is used at a concentration of 2%.(37) Thus in spite of the myogenic noise 
concomitant with the awake state, this is more preferable to get quality recordings though the 
time to recording increases.(38)  
6.8. Various stimuli used: 
6.8.1. Click- evoked ABR: 
The click-evoked ABR, otherwise called as transient-evoked ABR is the most commonly 
used electrophysiological procedure used for assessing the auditory thresholds in both infants 
and children. When the stimulus is given in the form of an abrupt onset of click at moderate 
intensity levels, a major portion of the cochlea is activated which results in firing of a large 
network of neurons over an extended frequency range. The most constant and highly 
repeatable waveform is waveform V that can be detected within about 10 decibels intensity 
level of the average behavioural audiogram in the 1 kHz to 4 kHz frequency region in both 
children and adults. The main limitation of the click-evoked ABR in prediction of the 
threshold is its lack of frequency speciﬁcity. 
39 
 
6.8.2. ABR - tone bursts: 
Tone bursts are gated sinusoids that are brief enough to produce the synchronous neural 
discharge which are required for a measurable ABR, still with suﬃcient duration, in order to 
retain some frequency specificity. Tone bursts may show better results in predicting 
peripheral sensitivity than the click-evoked responses, particularly in the cases of sloping or 
other unusual audiometric conﬁgurations. The waveforms, here, are seen to be longer in 
latency than those that are generated by click stimuli. There is a delay in the responses to 
low-frequency stimuli, as the time travel to reach the more apical turns of the cochlea is 
increased. In order to include these delayed peaks, the analysis window should be extended 
to 20 ms or more while recording ABRs to tone bursts, especially for tone-burst frequencies 
below 2000 Hz. When adequate stimulus and appropriate acquisition parameters are used, the 
results can be obtained at intensity levels within 10 dB of the behavioural thresholds for 
identical frequency stimuli, yet the correction factor may be nearer to 20 dB for 500 Hz and 
below. 
6.8.3. Bone conduction ABR: 
Bone-conduction ABRs can be as consistent and repeatable as air- conducted ABRs 
especially where signal delivery show a tight control. In young children, bone conducted 
ABR is mainly useful in assessing if a functioning cochlea in the presence of structural 
anomalies exists, like ear canal atresia. Oscillator location and coupling force seem to be 
prime factors in bringing out reliable bone-conduction ABRs. 
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6.9. Procedure: 
The Brainstem Auditory Response estimates the electrical activity of the eighth nerve 
through the brainstem to the auditory cortex. Here, a sound stimulus in the form of a click is 
presented to one ear at a time. The electrodes placed on the scalp records the various 
electrical activity of this signal. The average of the responses is shown as a waveform which 
contains troughs and peaks that correspond to the various points along the auditory pathway.  
The time taken between these peaks is measured and is compared to normal data. A delayed 
response indicates an abnormal response. The individual peak latencies and inter-peak 
latencies along with the other waveform morphology are measured. Peak latencies, amplitude 
and morphology of the waveforms offer reliable information about the integration and 
maturation of the eighth nerve and lower brainstem pathways. 
6.10. Prerequisites: 
An ABR recording may become contaminated by non-physiologic artefact, particularly, 60-
Hz interference that is partially phase-locked. Efforts must be made to reduce the electrode 
impedance asymmetries and reducing the source of artefacts. As ABR involves recording of 
electrical evoked potentials that are graphically represented, patient sedation is required to 
avoid any additional sound stimuli. Any movement artefact may interfere with the 
morphology of the waveform responses and thus the interpretation. It is performed 
satisfactorily in adults when they sleep, but becomes difficult in those who don‘t sleep and in 
children. Pharmacological sedation thus becomes mandatory.  
 
41 
 
7. Need for patient sedation in children: 
 Recent advances and technological breakthroughs have led to a wide increase in the 
spectrum of effective diagnostic procedures and therapeutic interventions in the medical 
field. In audiology, newer equipments and devices have come into practice providing 
solutions to the often faced diagnostic dilemma in many situations. This has led to a 
significant reduction of the burden faced by both the physicians and the patients. Not 
infrequently, these delicate tests require patient sedation.  
Many procedures in adults can be performed under local anaesthesia and reassurance. While 
in infants and children, this is not the case as it may not often be possible because they may 
be too frightened even if the procedure itself is not painful. Hyper-active children add to 
further difficulty. Patient movement and agitation may lead to myogenic and movement 
artefacts, threshold overestimation ultimately leading to inaccurate recordings.(22) 
Performance of any diagnostic or interventional procedure on children is safer and is more 
likely to be successful when the child does not move or when the associated anxiety, fear and 
stressful environment are adequately and appropriately tackled well. In addition, considerable 
attention to the patient‘s pain and anxiety is a requisite of acceptable and compassionate 
patient care. Very often, unlike adults, children are not candidates for reassurance or 
disciplined obedience. Pharmacologic and non-pharmacologic interventions as per the child‘s 
developmental status and the clinical circumstances need to be considered. Non-
pharmacologic measures are not always successful. The procedure may get interrupted and 
providing a non-pharmacologic measure to induce sleep again may turn futile. This may 
interfere with the quality of the recordings and add to the time consumption. The 
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environment in which most of these tests are conducted warrants a calm and quieter setting 
with dimmer lights for effective readings. Children when they wake up in between tests to 
find themselves in such an unfriendly environment get frightened making it difficult for even 
their parents to calm them down. The chance and possibility of re-sedation in such a 
circumstance using non-pharmacological measure become questionable. It is not rare that 
these un co-operative children become candidates for General Anaesthesia for effective 
completion of these essential diagnostic tests.(39) This further increases the time, cost and 
waiting lists for operating theatre on one hand besides building up anxiety among parents on 
the other hand, not to forget the ill-effects of anaesthesia these children are exposed to when 
it could possibly be avoided if options prevail. The increased availability of newer and short-
acting sedatives along with accurate non-invasive monitoring has enabled patient sedation 
especially paediatric sedation a possible task.(40)  
There is no absolute indication for the performance of paediatric procedural sedation. It may 
be used for any procedure which warrants absolute movement restriction or where a child‘s 
pain and anxiety may be excessive which may impede the performance of a procedure. The 
need for sedation again varies with the age, developmental and behaviour status of the child. 
The targeted depth of sedation and the pharmacological drugs used depend on the procedure 
for which sedation is warranted besides the patient factors. Some of the procedures that 
commonly mandate procedural sedation in children include imaging by computed 
tomography or magnetic resonance imaging, electroencephalogram, orthopaedic procedures 
like fracture reduction, complex laceration repair, large abscess incision and drainage, 
instrumentation like endoscopies, Bronchoscopy, burn dressing change, central line 
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placement. In the field of oto-rhino-laryngology, ABR is one of the procedures which 
warrant strict movement restriction for effective completion and quality recordings.  
8. Guidelines for paediatric sedation: 
 Procedural sedation and analgesia implies the use of a pharmacologic technique to allay 
patients fear and anxiety. It is seen as an effective, safe and a humane way to aid appropriate 
medical care. The goals for procedural sedation could be pain relief, anxiolysis or both and 
the desired effect could be achieved using varied cocktails of medications, besides handling 
safe the various adverse effects associated with them.  
The trend of paediatric procedural sedation has opened new domains for managing un co-
operative paediatric patients in almost all disciplines of health care.(41)(42) This has enabled 
safe and effective performance of diagnostic and therapeutic procedures in the outpatient 
setting. Coupled with the emergence of promising pharmacologic agents and non-invasive 
monitoring, this new and recent surge has led to a phenomenal growth in the volume and 
scope of safe and effective paediatric procedural sedation.(43) 
For any sedation, safe implementation of practice protocols is essential. The aims of sedation 
during diagnostic procedures and therapeutic interventions should include allaying fear and 
anxiety, bringing pain control and minimizing physical discomfort and movement, the 
importance of each of which depends on the patient characteristics and the procedure 
proposed. Many sedation techniques available are studied and are being implemented but 
there is inadequate direction and assistance on which techniques are effective and what 
resources are needed to administer them safely.  
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There are no absolute contraindications to procedural sedation in children. Relative 
contraindications include anticipated difficult airway or significant medical co-morbidities. 
Prior to sedation, written informed consent has to be obtained from the parents after 
discussion about the risks, benefits, alternatives for sedation.   
8.1.  Classification  
As a part of pre-sedation evaluation, American Society of Anaesthesiologists classification of 
risk stratification should be given to every patient that assesses patient appropriateness for 
elective procedural sedation. 
ASA I - healthy normal patient 
ASA II – mild systemic disease (e.g., mild asthma, controlled diabetes mellitus) 
ASA III – severe systemic disease (e.g., moderate to severe asthma, un-controlled diabetes 
mellitus) 
ASA IV –severe systemic disease which poses a constant threat to life (e.g., advanced 
cardiac disease) 
ASA V – a moribund patient who is not expected to survive without the operation (e.g., 
severe trauma, septic shock) 
Although the ASA classification was not specifically designed to rate sedation risk, it appears 
to correlate with appropriateness for sedation.  
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Sedation among children is regarded as a continuum and is graded as minimal, moderate and 
deep.(44)  
According to the American Society of Anaesthesiologists and American Academy of 
Paediatrics, sedation is classified as follows: 
Minimal sedation or anxiolysis (old terminology): 
A state of consciousness which is drug induced during which patients react normally to 
verbal commands. The ventilatory and cardiovascular functions are undisturbed although 
coordination and cognitive function may be hampered. 
Moderate sedation or conscious sedation or sedation/analgesia (old terminology):  
A state of depressed consciousness which is drug induced during which patients react 
purposefully to verbal commands (e.g.: ―open your eyes‖ either alone or along with light 
tactile stimulation—a light tap on the face, shoulder but not a sternal rub).  
In older patients, moderate sedation may be implied by an interactive state while younger 
patients are expected to respond by age-appropriate behaviours (e.g. crying).  
With moderate sedation, no intervention is needed to maintain a patent airway. Spontaneous 
ventilation is maintained. Cardiovascular function is generally maintained.(44) 
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Deep sedation (Deep sedation/analgesia):  
A state of consciousness which is drug induced during which patients cannot be aroused 
easily but may respond purposefully after continuous painful or verbal stimulation (e.g. 
pushing away the noxious stimuli purposefully). The ability to maintain ventilatory function 
independently may be impaired such that patients may need support in maintaining a patent 
airway. Spontaneous ventilation may be inadequate, but, cardiovascular function is usually 
maintained. This state of deep sedation may be accompanied by partial or complete loss of 
protective airway reflexes. 
General Anaesthesia:  
A state of consciousness which is drug induced during which patients are not arousable, even 
to painful stimulus. The ability to maintain respiratory function independently is often 
impaired such that patients often require assistance in maintaining a patent airway. Positive-
pressure ventilation may be required due to depressed spontaneous ventilation or drug-
induced depression of neuromuscular function. Also, cardiovascular function may be 
impaired. 
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Sedation levels and Clinical Response: 
 Verbal 
Response 
Pain 
Response 
Airway 
Response 
Breathing Circulation 
Anaesthesia 
overdose 
0 0 0 0 0/+ 
Anaesthesia 0 0 0 0/+ 2+ 
Deep Sedation 0 1+ 1+ 2+ 3+ 
Moderate Sedation 1+ 2+ 2+ 3+ 5+ 
Minimal Sedation 3+ 4+ 4+ 5+ 5+ 
No 5+ 5+ 5+ 5+ 5+ 
 
Moderate sedation earlier called as conscious sedation is evolving as an effective way for 
paediatric procedural sedation. With fast evolving diagnostics and therapeutics, many 
Professional organizations are working towards this promising lane.(45–48) The American 
Society of Anaesthesiologists has updated and revised its guidelines for providing effective 
and safe paediatric procedural sedation and analgesia by non-Anaesthesiologists in the 
office-setting.(48)  
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8.2. Sedation by non-anaesthesiologists: 
Children who belong to ASA class I and II are generally eligible for mild, moderate and deep 
sedation by personnel other than anaesthesiologists, outside the operating theatre. Those with 
ASA class III, IV, V may not be candidates for similar ways of sedation.  Several studies 
have put forward guidelines and protocols for administering paediatric sedation by non-
anaesthesiologists. Specific paediatric guidelines are established by the American Academy 
of Paediatrics (AAP) and the most important recommendation common to all guidelines is 
related to the person performing the sedation. The administering person must be adequately 
qualified enough to manage all potential complications ranging from airway-respiratory 
compromise and hemodynamic instability.  
The setting must be sufficiently supported with age appropriate and adequately sized 
equipments and medications besides monitors while performing paediatric procedural 
sedation and the practitioner should be capable to rescue the child from a deeper level of 
sedation than that was intended. Equipments must include oxygen, suction, bag-mask 
ventilation device, intubation equipments. Necessary monitors to monitor saturation and 
heart rate should be available. Blood pressure monitoring should be available except in 
situations where this may itself interfere with the sedation and thus the procedure. Sedation 
by non-anaesthesiologists is safe if all the measures are followed.(41)(49)  
8.3. Fasting status: 
The duration of pre-procedural fasting guidelines is controversial. According to the ASA 
guidelines, the child to be sedated should be kept nil orally for 6 hours before the procedure 
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for infant formula or a light meal, 4 hours for breast milk and 2 hours for clear liquids. As it 
is not always feasible to maintain strict fasting guidelines when it comes to children, the 
practitioner administering the sedation should take this into consideration and be prepared to 
rescue the child in the unforeseen circumstances.  
8.4. Discharge criteria: 
After procedural sedation, children should be monitored till they are awake up to their 
baseline mental status and are ambulatory. The parents must be educated on the discharge 
instructions at discharge, emphasizing on the possible complications like respiratory distress. 
They should not participate in activities requiring coordination for 24 hours and should not 
swim unattended for 8 hours.  
9. Pharmacology for paediatric procedural sedation: 
There is a wide range of pharmacological drugs used for paediatric procedural sedation 
including Opioids, Benzodiazepines, and Barbiturates, sedative- hypnotic agents, and other 
induction hypnotic agents like propofol, ketamine, and nitrous oxide. The choice of drug 
depends on the type of procedure, patient status and age, the targeted depth of sedation, co-
morbidities if any associated. Procedures which are not painful warrant only sedation and not 
analgesia. ABR is a non-invasive procedure which mandates procedural sedation in children.  
9.1. History of sedative agents: 
The evolution of sedative drugs began when the Sumerians introduced fermented beverages 
in 9000BC. Besides, ether and nitrous oxide, the 19
th
 century marked the beginning of the 
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modern age of sedative medications with bromides and chloral hydrate. As Bromides could 
not be manufactured into elegant pharmaceutical products, the impurities added along 
resulted in much unwanted side effect profiles. It was the German chemist, Justus Von 
Liebig, in 1832, synthesized Chloral hydrate which denoted the first class of sedative drugs 
to extend longevity. It is a CNS depressant with rapid onset of action approximately 30 
minutes. Soon, it was combined with alcohol to bring out the best of the cocktail 
preparations.  
9.2. Barbiturates: 
The early twentieth century popularized many of the sleeping pills, the most popular among 
them being the Barbiturates. Invented by the Prussian chemist, Adolf Von Beyer, 
Barbiturates are an excellent sedative and sleeping aid and a myriad of derivatives emerged 
in the 1920s and 1930s by many of the American and European pharmaceuticals. These 
effective sleeping pills were not without side effects, especially, their addictive behaviour, 
unpleasant side effects and the exaggerated CNS depressant activity when combined with the 
other similar drugs or with alcohol causing significant respiratory depression. This narrow 
safety margin prompted the budding of safer and newer sedative – hypnotic in the following 
decades. 
9.3. Chloral hydrate: 
Chloral hydrate is a non-opioid, non-barbiturate sedative-hypnotic drug used since many 
years.  Chloral hydrate, first synthesized in 1832 by Leibig is known to be one of the oldest 
and synthetic sedatives, brought into use since 1869 (50). Although it faced a decline from 
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the end of the 19
th
 century to the middle of the 20
th
 century, it was used principally as a 
paediatric sedative agent for many of the dental and diagnostic procedures in the 1990‘s. 
Though chloral hydrate is a CNS depressant, the actual mechanism of action is not known. 
Butler in 1948 discovered the principal active metabolite, Trichloroethanol besides the 
trichloroacetic acid, both of which were formed by the erythrocytes and hepatocytes. The 
sedative effect is attributed to chloral hydrate while the hypnotic effect to the metabolite, 
trichloroethanol. It is available in the oral and rectal forms. The drug was rapidly absorbed in 
the gastrointestinal tract with a high lipophilicity. The sedative and hypnotic effect was 
brought out in 20 to 60 minutes. It had a short half-life within a few minutes while the half-
lives of the metabolites are longer, 8 to 12 hours for trichloroethanol and nearly 67 hours for 
trichloroacetic acid. It is eliminated principally by the kidneys. It shows a wide range of 
interactions with many drugs like, alcohol, anticoagulants, amitriptyline, and furosemide. It 
has been showed that Flumazenil, a GABA antagonist has been used in cases of intoxication 
which indicates a possible GABA mediated action. The usual dosing is between 0.5 to 2gm 
per day and is taken during meals to prevent gastric irritation. The chief side effects are due 
to its CNS depressant and arrhythmogenic potential. The adverse effects range from 
digestive, cardiac (risk of dysrrhythmias due to myocardial sensitization of catecholamines 
by trichloroethanol), dermatologic, neuropsychiatric like withdrawal reactions, delusion, 
hallucinations, dependence and ophthalmologic reactions. Intoxication with death occurs 
after absorption of doses of around 10 gm of chloral hydrate, some cases reporting even with 
5gms. There are reports on genotoxicity and carcinogenicity reported in the literature. It 
crosses the placenta and enters breast milk. Some of the studies say that chloral hydrate can 
be used as a paediatric sedative only once in a lifetime.  
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Use is contraindicated in cases of gastric ulcers, hepatic and respiratory insufficiency, 
porphyria, known hypersensitivity.  
9.4. Benzodiazepines: 
Benzodiazepine group of drugs with its newer derivatives are the commonly used 
medications for sedation & anxiolysis. The core chemical structure shows a fusion of 
benzene ring and a diazepine ring. 
 
Fig.9: The core structure of Benzodiazepines.  
The label ―R‖ denotes common locations of side chains that give different benzodiazepines 
their unique properties.  
Chlordiazepoxide, the first benzodiazepine was discovered accidentally in 1955 by Leo 
Stembach when working for the Hoffman-LaRoche company. Since then, it gained wide 
popularity and gained attraction especially for its enviable safety profile when compared to 
the other class of drugs. More than 15 different types of benzodiazepines exist today for 
various indications.  
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Their specific action on the central nervous system is exhibited by promoting the binding of 
the inhibitory neurotransmitter GABA (gamma amino butyric acid) to the Benzodiazepine 
receptors on the GABAA subtype of the GABA receptors. These receptors are multiple 
subunit complexes and are closely related with chloride gated ion channels within the 
neuronal cell membrane. When the receptor is activated, it causes opening of the chloride ion 
channel facilitating greater chloride ions influx besides a more negative (RMP) resting 
membrane potential that results in the neuron being less responsive to excitatory stimuli.(47) 
As the benzodiazepines do not cause direct opening of the chloride channels, but bind to 
specific BZD receptors on the GABAA complex which is separate from the actual receptor 
for the GABA, it only enhances the chloride ion channels response to GABA and in the 
absence of GABA, there is no effect produced. A benzodiazepine agonist can only cause 
potentiation of the body‘s endogenous neurotransmitter which explains the relative safety 
profile of benzodiazepines. The wide therapeutic index of benzodiazepines is explained. The 
effective-dose (ED50) curve and lethal dose (LD50) curve shows a very wide margin, such 
that the very large doses required for ‗hypo-responders‘ are less likely to cross the brain 
barrier.  
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Fig. 10: Benzodiazepine dose response curve.  
Almost all of the drugs belonging to this class show a similar sedative and safety profile with 
minor differences in the duration and onset of clinical effects among individual drugs. They 
are known for their various actions including sedation, hypnosis, anxiolysis, muscle – 
relaxant, anterograde amnesia and anticonvulsant actions.(51) Diazepam is the prototype of 
the benzodiazepines and Lorazepam is considered as an intermediate acting one. The next in 
the group is midazolam. Midazolam belongs to the short acting group and is the most 
common drug considered suitable for paediatric procedures in view of its rapid onset of 
action, short elimination half-life, its anaesthetic sparing effect and rare occurrence of serious 
side effects. This facilitates faster recovery process and thus preferred for ambulatory, day 
procedures. 
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9.5.    Midazolam 
Midazolam is a 1, 4, imido-benzodiazepine with unique chemical structure and physical 
properties. It was developed in the 1970s by Hoffman-La Roche and has emerged as one of 
the effective and rapid-onset and short-acting benzodiazepines. The salts of Midazolam are 
water soluble and are stable in aqueous solution. The oral bio-availability is 35 to 44 % and it 
has a rapid onset of action within 15 to 30 minutes to show a peak plasma levels within 20 – 
50 minutes. The drug is water soluble (pH less than 4) in the commercially prepared 
formulation but becomes lipid soluble (pH more than 4) at physiological pH, in the form of 
diazepine closed ring form, when it crosses the blood brain barrier to exert its clinical effect 
contributing to the rapid onset of action. It is metabolized in the liver by the enzyme human 
cytochrome p450 (CYP3A4) system to its pharmacologically active metabolite alpha-
hydroxyl midazolam and 4- hydroxyl midazolam. It is extensively protein bound and the half 
life ranges from 0.8 to 1.8 hours. It is excreted primarily by the kidney.(52) It is routinely 
dosed at 0.2 to 0.5 mg/kg.(53)    
The various routes of administration have been studied extensively and include intravenous, 
intramuscular, sublingual, buccal, rectal, oral and intranasal.(54) Because  in children of 
aversion to needles, oral, rectal, sublingual and nasal routes seem reasonable besides 
avoiding the risk of needle stick injuries.(55) The unpleasant bitter taste may not be liked by 
children and the extensive first pass metabolism may reduce the bioavailability of this drug 
when administered orally and thus may require administration of large doses which may not 
be without adverse effects.(56)(57) Sublingual route may be beneficial in this regard but 
difficulty in achieving the child‘s cooperation in keeping the drug under the tongue for at 
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least thirty seconds for desirable efficacy of the drug pose problem.(58) Rectal route may 
bypass this effect but may be result in unpredictable absorption rates besides adding 
discomfort to the child and being embarrassing especially in older children.(59) Thus 
disadvantages of these routes include painful injection, slow onset, unpredictable and delayed 
recovery. These effects can be overcome by the intranasal route of drug administration. The 
high nasal mucosal vasculature offers intranasal route in the faster and complete absorption 
of the drug into the systemic circulation.  The ease of administration, avoidance of needle 
injuries and high predictability have made this route of administration popular.(60) 
Intranasal Midazolam has been known to be in use for over a decade in providing paediatric 
procedural sedation in various divisions of health care. Dental procedures like tooth 
extractions, paediatric emergency room procedures like repair of nasal lacerations, 
orthopaedic reduction of fractures, oral and maxillofacial trauma, ophthalmological 
procedures like fundus examinations and nasolacrimal duct repair, peripheral line and central 
venous cannulations, diagnostic upper GI endoscopies, imaging like CT, MRI, paediatric 
burn patients, electroencephalogram and echocardiogram are some of the areas of its 
application.(61–79) The dosing ranges from 0.2 to 0.5 mg/kg for the intranasal 
formulation.(80) The side effect profile has been reported from common events like 
sneezing, lacrimation, stinging of mucosa and hiccups at the time of nasal spray.(80,81) This 
is mainly due to the preservative contained in the intranasal formulation of Midazolam. As 
with any other drug, hypersensitivity reactions are known to occur. Children sometimes 
exhibit paradoxical emergence reactions like disinhibitions, agitation, restlessness and 
hallucination. Infrequently, dose-related adverse effects are reported which include 
prolonged sedation, seizures, respiratory depression, hypoxia, desaturation that require 
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transient administration of oxygen and rarely cardio-respiratory arrest requiring mechanical 
ventilation.(82–84) Thus continuous monitoring becomes essential which avoids such serious 
mishaps that can be picked up early and managed appropriately. The antidote to overdose 
exists in the form of Flumazenil which reverses the effects at the receptor level.(85)(86) It 
has been observed from studies that Midazolam when administered alone is found safe and 
the mentioned serious effects are commonly found when administered in combination with 
Opioids.  
Thus, in this regard, we propose to study the efficacy and safety profile of Midazolam nasal 
spray for paediatric procedural sedation for auditory brainstem evoked response audiometry 
and compare it with the standard drug used for ABR, syrup chloral hydrate. 
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Materials and methods 
Design: 
It was a prospective, randomized, double-blinded, placebo controlled trial. 
Setting: 
The study was conducted in a tertiary care hospital. It is a 2, 600 bedded hospital which 
caters to nearly 1, 20, 000 inpatients and 1.9 million outpatients annually with 45 births, 125 
operations and nearly 25, 635 various laboratory tests carried out each day. The Department 
of ENT caters to nearly 35 to 40 % of the paediatric age group. Nearly 15 to 20 children per 
week undergo Auditory Brainstem evoked Response audiometry (ABR) in the department. 
The audiology room in the Department of ENT was equipped with appropriate emergency 
resuscitation requirements. 
Recruitment of patients: 
The patients for the study were recruited from the Department of ENT.  Parents or care 
givers of patients who were referred for Auditory Brainstem evoked Response audiometry 
(ABR) for hearing loss were invited to participate in the study. The study was conducted 
from January 2012 till June 2013. 82 patients were recruited according to the statistical 
requirement and the inclusion, exclusion criteria.  
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Institutional Review board: 
The study was approved by the Institutional Review board and the Ethics committee. The 
research funding was obtained from the fluid research grant of the institution.  
Inclusion criteria: 
All children in the age group of 1 to 6 years referred for ABR irrespective of their 
developmental maturity. 
Exclusion Criteria: 
1. Refusal for the procedure 
2. Hypersensitivity to Midazolam 
3. Nasal allergy 
4. Obesity with a body mass index more than or equal to 30 
5. ASA grade more than 2 
Medications used: 
Syrup Chloral hydrate (gold standard) is routinely used in our department to induce 
paediatric sedation at a dosage of 50 mg/kg. It is manufactured as syrup Triclofos sodium by 
the American Remedies Limited (100 mg/ml bottle, available in 5 ml and 30 ml). It is 
60 
 
repeated twice if the expected level of sedation is not achieved. The second dose is repeated 
at half the dosage and the maximum dose that can be attained is 100 mg/kg.  
The interventional drug was Midazolam nasal spray (Samarth Pharma Pvt. Ltd, Mumbai), 
available as INSED Atomiser with 50 MD - 0.5 mg per metered dose. The number of sprays 
required for a dose of 0.5 mg/kg was calculated and administered. In case of second dosing, 
it was calculated at half the dose and administered as spray.  
Placebos were prepared for both the preparation.  
The Department of Pharmacy at the hospital provided the placebos for syrup Triclofos. The 
manufacturers of Midazolam nasal spray (INSED atomizer), the Mumbai based Samarth 
Pharma Pvt. Ltd. provided the placebo nasal spray. The placebo was packaged as INSED 
nasal spray, 0.5 mg x 1 puff x 50 md (metered doses) and was prepared in such a way that the 
composition and the preservative remained the same except the active drug.  
The active drugs, both Midazolam nasal spray and syrup Triclofos were purchased from the 
pharmacy using the fluid grants fund. The Midazolam placebos were sent by the 
manufacturers and Chloral hydrate placebos were prepared by our pharmacy. The drugs and 
the placebos were packeted according to the randomization codes. 
Method of randomization: 
Block randomization with a block size of 2, 4 and 6 with 25%, 25% and 50% respectively 
was used. Computer automated generated codes were produced using SAS.9.1. A copy of the 
generated randomized codes was archived at the department of Biostatistics. One copy was 
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sent to the Department of Pharmacy to prepare identical drugs as per the randomization 
which was serially numbered with a marking of A and B. 
Method of allocation concealment: 
According to the computer generated randomized codes, opaque envelopes were prepared 
which were serially numbered and bound. Codes were broken after the analysis is over with 
the IRB permission letter. 
Blinding and Masking: 
Double blinding was done. Placebo was made for both Midazolam spray as well as for syrup 
Chloral hydrate so that every child who was randomized received both the spray and the 
syrup such that the chance of receiving the actual drug was one in two or fifty percent. This 
way, the patient and the doctor who administered the drugs were both blinded. The drugs 
were packeted by the pharmacist and were named drug A and B. It was made sure that the 
child received only one of the active ingredients at any time, either the standard practice or 
the interventional drug by either of the routes and the other route remained a placebo. This 
was done to bring out the actual efficacy and comparison between the two drugs.  
Primary outcome: 
1. Safety during the proposed procedure. 
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This is measured by assessing the below physiological parameters and intervention begins 
when 
a. Oxygen saturation (SpO2 below 90%) 
b. Respiratory rate (RR below 10) 
c. Heart rate (HR below 60) 
2. Efficacy during the proposed procedure. 
This is measured by  
 Satisfactory sedation in terms of completion of the procedure. 
 Level of consciousness – sleep and movement (lack of response or purposeful 
movement to verbal or tactile  stimuli) 
Secondary outcomes: 
1. Time for parental separation – the time that the child allows to be separated from the 
mother from the time the drug is given. 
2. Nature of separation from parents – on a scale of 1 to 4 
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Awake   and crying                                                                                    1 
Awake and Calm                                                                                       2 
Drowsy                                                                                                       3 
Sleepy                                                                                                         4 
3. Time taken for onset of sedation – the time of administration of the drugs to the time 
the child allows the electrodes to be placed. 
4. Duration of procedure – time when electrodes are placed to removal of electrodes 
5. Time taken for recovery – time from completion of procedure to time when child 
wakes up to pre-procedure level of consciousness 
6. Post recovery behaviour – on a scale of 1 to 4 
Irritated: awake, restless, crying                                1 
Normal: awake, calm                                                 2 
Inactive: tired, hardly moving                                    3 
Sleepy: drowsy, without reaction, but arousable       4 
7. Acceptance by parents – satisfied / dissatisfied 
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8. Audiologists satisfaction – on a scale of 1 to 3 
Poor – procedure aborted                                                  1 
Fair - procedure interrupted, but completed               2 
Good- procedure performed without any interruption      3 
9. Number of attempts 
The paediatric procedure sedation form and the scoring scales for various parameters are 
included in the annexure. 
Target sample size and rationale: 
Two means – Hypothesis testing for two means (equal variances) was used based on the 
primary outcome – duration of sedation. From literature, we found that the difference in 
means for the two different interventions was as follows, 
Standard deviation in group I  = 26.8 
Standard deviation in group II  = 29.4 
Mean difference                        = 24.1 
Effect size                                 = 0.85 
Alpha error (%)                        = 1 
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Power (%)                                = 90 
Sided                                        = 2 
Required sample size per group  = 41 
Thus we proposed to recruit 41 patients in each arm to study statistically significant results 
which accounted for 82 patients to be studied. 
Statistical analysis: 
Descriptive statistics were generated for all the samples. Chi-square test was used to analyze 
the descriptive variables with Pearson test and Fisher‘s exact test to study the statistical 
significance. Student t-test for equality of means was used to study the difference in means of 
the quantitative parameters. Kaplan Myer model was used to test the association between 
time of onset of sedation and time to recovery and compared the effect of developmental 
maturity on the same. Statistical significance was based on 2-sided tests with a probability 
value p of 0.05.  The results were computed using SPSS. 
Procedure: 
Parents or care givers of children referred for BERA were invited to take part in the trial. If 
they were willing to participate in the study and they met the inclusion and exclusion criteria 
they were recruited into the study. They were given the patient information sheet in their 
respective languages which included the need for paediatric sedation, the drugs used, and the 
double-blinded nature of the trial, the nature of the sedation and the procedure, the risks 
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associated the contact details in case of queries. They were verbally explained about the 
fasting status and the escort policy post procedure which was advised according to the 
American Society of Anaesthesiologists guidelines. They were also advised to come half an 
hour prior to the scheduled time of the procedure for pre-procedure evaluation. 
On the day of the procedure, after discussing the risks and the benefits of the trial, if the 
parents were willing to allow their child to participate in the trial, an informed consent was 
obtained. A brief medical history and examination was done with the child seated on the 
mother‘s lap. This also included assessing the fasting status, recording the weight of the 
child, a brief systemic and airway examination. The vital parameters were also recorded at 
baseline including heart rate and oxygen saturation using a portable pulse ox meter (Model: 
ECPO – 250E, batch no. 012011, Easy Care group, Mumbai) attached to the child‘s big toe 
or thumb whichever the child allowed,  respiratory rate by manually counting for one minute, 
level of consciousness – sleep and movement and developmental maturity. The Procedural 
sedation form was filled in as required.  
After the initial pre-procedural evaluation, the child was randomized according to the 
computer generated allocation codes provided. The packets which were serially numbered 
and the opaque envelopes were opened for every child. Every packet contained one nasal 
spray and one syrup. The nasal spray could be Midazolam or the placebo at a dose of 0.5 
mg/kg at a concentration of 100 mcg per spray divided between each nostril and the syrup 
could be Chloral hydrate or placebo at a dose of 50 mg/kg.  
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The allocation was done in such a way that at any time, the child was assured of only one of 
the drugs for sedation and the other route, remained a placebo. In this way, the child was not 
denied of the required sedation nor received both drugs together. Also, both the patient and 
the investigator were blinded so that the actual efficacy of the drugs brought out did not 
happen by chance and avoided any possible bias.  
The child and the mother were taken to a ‗quiet‘ room equivalent to a recovery room. The 
dose of the syrup was calculated according to the weight of the child and was given to the 
mother to administer to the child. Once the child swallowed the syrup, he / she were made to 
sit straight again on the mother‘s lap. The nasal spray was opened and after shaking, the first 
two sprays were pushed out in the air. Following this, it was introduced into the nasal 
vestibule of the child and the required calculated number of nasal sprays as per the weight of 
the child was sprayed equally between both the nostrils. Any agitated movement by the child 
during the spray was controlled by the mother and the drug administrator. Following this, the 
child was left with the mother and was monitored for the parameters. Once the child showed 
signs of parental separation, he / she were taken to the procedure room next to the recovery 
room and were placed on the procedure bed. If the child allowed placement of the electrodes 
on the scalp and the ear, the time was noted for onset of sedation. Throughout the entire 
procedure, the mother was made to sit inside the procedure room and the Doctor monitored 
the child for the vital parameters as mentioned and the behaviour of the child every 5 minutes 
as the audiologists carried on with the procedure in the standard way. Those children who did 
not sleep with the first dose of drugs were re-administered the drugs with half the original 
dose and again observed. If they did not sleep for almost one hour after the second dose, they 
were tagged, failed sedation. All children were evaluated till they attained the pre-drug 
administration vital signs and behaviour status.  
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During the procedure, any child whose oxygen saturation dropped below 90% was given a 
mild chin lift and a pillow under the shoulder if needed. Any movement interrupting the 
procedure or if the child woke up in between the procedure were noted down.  
The child was observed throughout the procedure using non-invasive monitoring at regular 
intervals of 15 minutes till onset of sedation and every 5 minutes then on.  
After completion of the procedure, the child was awakened and monitored in the recovery 
waiting area with the parents till he/she was back to pre-procedure level of normalcy. Once 
the child recovered, the parents were educated about the dietary advice, escort policy and the 
child was discharged as per discharge guidelines. Emergency resuscitation measures were 
available if required. The parents were provided with contact numbers to approach for 
medical help in case of adverse events after discharge.  
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Results 
The study was completed with 41 children recruited in each arm. The results were analyzed 
using appropriate statistical methods and results tabulated.  
All children in both arms were between the age group of 1 to 6 years with a mean age of 2 
years. The mean weight in kilograms was 11.9 among those who received Midazolam and 
12.4 in children who received chloral hydrate. Independent student t-test for equality of 
means was used which did not show any significant difference between the two groups and 
thus both arms were comparable.  
Of the 82 children who participated in the study, 55 (67%) were males and 27 (33%) were 
females. Of the male children, 68.3% received Midazolam and 65.9% received chloral 
hydrate. While 31.7% and 34.1% were females among those who received midazolam and 
chloral hydrate. 58% and 65% of children were developmentally normal among those who 
received Chloral hydrate and Midazolam respectively as against 41% and 34 % of the 
developmentally delayed ones. Children for whom ABR was indicated were grouped 
primarily into 3 categories as hearing impaired, speech delayed and those who suffered both. 
Nearly 20% of children were hearing impaired in both the arms. 53% of children who 
received Chloral hydrate and 56 % of children who received Midazolam were speech 
delayed, while 26% and 24% respectively suffered both. Chi-square tests were used with 
Pearson test which did not show any statistical difference between the groups as can be seen 
from tables 1.1 and 1.2. 
 
70 
 
Comparable characteristics between the two groups:  
Table 1.1 
 
Table 1.2 
Parameters 
Midazolam 
( n = 41) 
Chloral hydrate 
( n = 41) 
Total  (n=82) p 
value 
n % n % n % 
 
Males  
Females  
 
28 
13 
68.3 
31.7 
27 
14 
65.9 
34.1  
55 
27 
67.1 
32.9 
0.814 
Development  
Normal  
Abnormal 
 
27 
14 
 
65.9 
34.1 
 
24 
17 
 
58.5 
41.5 
 
51 
31 
 
62.2 
37.8 
 
0.494 
Hearing impaired 
Speech delay 
Hearing & speech 
impaired 
 
08 
23 
10 
 
19.5 
56.1 
24.4 
 
08 
22 
11 
 
19.5 
53.7 
26.8 
 
16 
45 
21 
 
19.5 
54.9 
25.6 
 
0.966 
Parameters Midazolam 
( n = 41) 
Chloral hydrate 
( n = 41) 
 
p value 
Mean SD Mean SD 
Age (in years) 2.66 1.527 2.78 1.33 0.701 
Weight (in Kgs) 11.95 3.500 12.41 3.62 0.557 
Baseline Heart rate (in mins) 110.78 11.13 110.65 9.45 0.952 
Respiratory rate 25.95 3.01 25.71 2.54 0.698 
Oxygen saturation % 98.23 0.85 98.29 1.01 0.791 
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Fig. 1:  Graph - comparing the baseline characteristics. 
 
1. Primary outcome  –  a. safety: 
The primary outcome being safety was measured in terms of the physiological parameters 
such as heart rate, respiratory rate and oxygen saturation and both groups did not show any 
statistically significant difference. Heart rate less than 60 beats per minute, respiratory rate 
below 10 and oxygen saturation below 90% were considered not safe. There were no 
significant adverse effects noted. Both drugs were observed to be safe at all time intervals 
pre-sedation and post- sedation till recovery.  
At baseline, both the groups had comparable readings of these parameters as shown in table 
2.1.  The mean and standard deviation of these parameters pre-sedation and post sedation for 
individual drug groups and comparative statistics are tabulated. Both were found safe.  
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Table 2.1 
Pre - sedation 
Midazolam group 
(Mean ± SD) 
Chloral hydrate 
group (Mean ± SD) 
p value 
 
Heart rate (bpm) 110.78 11.125 110.65 9.453 0.952 
 
Respiratory rate 25.95 3.006 25.71 2.538 0.698 
 
Oxygen saturation % 98.23 0.848 98.29 1.009 0.791 
 
Table 2.2 
Post - sedation 
Midazolam group 
Chloral hydrate 
group p value 
Mean SD Mean SD 
 
Heart rate (bpm) 
 
102.18 
 
9.83 
 
102.98 
 
8.60 
 
0.748 
 
Respiratory rate 
 
23.93 
 
1.85 
 
24.71 
 
2.49 
 
0.218 
 
Oxygen saturation % 
 
97.47 
 
1.31 
 
97.31 
 
1.27 
 
0.655 
The parameters were checked pre-sedation at intervals of 15 minutes and at 5 minutes 
intervals post sedation. There were two episodes in the same child who had a transient 
oxygen de-saturation to 89% which improved promptly with mild chin lift and position 
adjustment of the child. This did not require any airway manipulation or invasive methods. 
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The child belonged to the Midazolam group (1 of 39 children who slept, i.e., 2.6%) and this 
effect was seen at 10 minutes and 25 minutes post sedation. p value was found to be 1.00 and 
thus was not significant. The remaining parameters were found to be within normal limits 
throughout the procedure and till recovery. Thus both the drug groups were found to be safe 
at all levels.  
1. Primary outcome  –  b. efficacy: 
The other primary outcome is efficacy which is measured in terms of  
 Satisfactory completion of the procedure and  
 Level of consciousness in terms of sleep and lack of movement during the procedure.  
Table 3 
Overall outcome 
Midazolam Chloral hydrate Total 
p value 
n % n % n % 
 
Successful sedation 21 51.21 38 95.12 59 72.0 
 
 
 
< 0.01  
Failed  20 48.8  03 04.9 23 28.0 
Total  
41 100 41 100 82 100 
The numbers of children who were successfully sedated overall and lead to the completion of 
the procedure in the Midazolam group were 21 and in the Chloral hydrate group were 38.  
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This was found to be statistically significant.  
 
Fig. 2:  Diagram comparing the outcome between Midazolam and Choral hydrate 
Following the onset of sedation, it was observed that children in both the arms slept 
throughout the procedure and there was no statistically significant difference in terms of 
interrupted sleep to abort the procedure.  
While considering movement, the first 3 categories in the scoring scale were combined as 
‗movement‘ and the score 4 remained as ‗no movement‘. It was observed that, following 
onset of sedation, in both the groups, children achieved a score of 4 during intra-procedure 
and did not show any lesser scores to interrupt with the procedure.  
 
 
 
Outcome -
Midazolam 
successful 
failed
Outcome - Chloral 
hydrate
successful 
failed 
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2. Secondary outcomes: 
2a.  Onset of sedation: 
Among those children (41 in each arm) who were given the drugs, at the end of 30 minutes, it 
was observed that 7 children among the Midazolam group and 26 children among the Chloral 
hydrate group had slept. This was statistically significant 
In other words, 7 (33.3%) children among those who were sedated in the Midazolam group 
and 26 (63.41%) of those in the Chloral hydrate group showed onset of sedation at 30 
minutes or earlier.  
Table 4.1 
Onset of sedation 
Midazolam 
n (%) 
Chloral hydrate 
n (%) 
p value 
<= 30minutes 
>30minutes 
07 (33.3 ) 
14 (66.7 ) 
26 (66.7) 
12 (33.3 ) 
 
0.017 
Total sedated 21 / 41 (51.21) 38 / 41 (95.12) 
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Fig. 3: Comparison between Midazolam and Chloral hydrate for onset of sedation at 30 and 
60 minutes.   
14 (66.7 %) children out of the 21 who slept overall among the Midazolam group and 34 
(87.2 %) children out of the 38 who slept among the CH group had onset of sedation at 60 
minutes. But statistically, this did not show any significance as shown in table 4.2. 
Table 4.2 
 
 
Onset of sedation 
Midazolam 
n (%) 
Chloral hydrate 
n (%) 
 
 
p value 
 
<= 60minutes 
>60minutes 
14 (66.7 ) 
07 (33.3 ) 
34 (87.2) 
04 (12.8 ) 
 
 
0.09 
 
Total  21 / 41 (51.21) 38 / 41 (95.12) 
Onset of sedation at 
30minutes
Midazolam 
Chloral 
hydrate
Onset of sedation at 
60 minutes
Midazolam
Chloral 
hydrate
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At the end of 60 minutes, there was no statistical significance between the groups. It was 
noted that 33% among the Midazolam group and 12.8% among the chloral hydrate group had 
delayed onset of sedation later than 60 minutes as shown in table 4.2.    
The figure below shows the results graphed by Kaplan Meyer‘s cumulative survival 
comparing onset of sedation between the two groups. It was found that children in drug 
group B, i.e., Chloral hydrate showed earlier onset of sedation than those in group A with 
Midazolam.             
 
Fig. 4: Kaplan Meyer graph comparing Midazolam (A) and Chloral hydrate (B) for onset of 
sedation. 
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2a.1. Effect of developmental maturity on sedation: 
Among the children who had slept, i.e., in 21 of 41 among the midazolam group and 38 of 41 
among the chloral hydrate group, the developmental maturity was compared as an affecting 
factor.    
  Table 5.1 
Developmental 
maturity 
Midazolam Chloral hydrate Total recruited 
p value 
n % n % n % 
 
Normal  
Abnormal  
27 
14 
65.9 
34.1 
24 
17 
58.5 
41.5 
51 
31 
62.2 
37.8 
 
0.494 
 
Total 
recruited 
41 41 82 
 
 
It was seen that among children who received sedation with both the regimes, more than half 
were developmentally normal. Among those children who slept, a significant difference was 
found between developmentally normal and the delayed children between the two groups.        
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Table 5.2 
Developmental 
maturity 
Midazolam 
n (%) 
Chloral hydrate 
n (%) 
Total 
 
p value 
 
 
Normal  
Abnormal  
12 (57.14 ) 
09 (42.85 ) 
22 (53.65) 
17 (41.46 ) 
34 
26 
 
 
 
0.006 
 
Total sedated 21 / 41 (51.21) 39 / 41 (95.12) 60 / 82 
 
 Fig.5:  Kaplan Meyer graph comparing Midazolam (A) and Chloral hydrate(B) among 
developmental normal children for onset of sedation. 
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Children in Midazolam group (A in figure) and who were developmentally normal still took 
a longer time for onset of sedation when compared to similar children in the CH (B in figure) 
group. Likewise, similar results were obtained between the two groups among 
developmentally delayed children. p value was found to be 0.012.  
Fig.6: Kaplan Meyer graph comparing Midazolam (A) and Chloral hydrate (B) among 
developmentally abnormal for onset of sedation.          
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    Table 5.3  
Developmental 
maturity 
Median for time to onset of sedation in minutes 
p value 
Estimate Standard error 
Normal  
Abnormal  
30.00 
20.00 
8.731 
4.780 
 
0.116 
                                
Fig.7: Kaplan Meyer graph comparing developmental normal (A) and developmental 
abnormal (B) children for onset of sedation.  
On the whole, developmental delayed children showed an earlier time to onset of sedation 
when compared to developmental normal children, but the difference was not statistically 
significant. 
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2b.   Time for parental separation: 
Time taken for children to be separated from their parents following drug administration was 
found to be significantly different at the end of 30 minutes between the groups.  
Table 8 
Time for parental separation 
Midazolam 
n (%) 
Chloral hydrate 
n (%) 
p value 
<= 30minutes 
>30minutes 
12 (52.2 ) 
11 (47.8 ) 
30 (71.4) 
09 (23.1 ) 0.05 
Total  23 / 41 (56.09%) 39 / 41 (95.12%) 
23 and 39 children in each arm allowed parental separation of which 71 % of the children 
among the Chloral hydrate group allowed themselves to be separated from their parents 
while only 52 % among the Midazolam group could be separated at the end of 30 minutes.  
Thus, on the whole, children who received Chloral hydrate showed earlier parental separation 
with onset of sedation compared to those who received Midazolam which was statistically 
significant. 
Table 9 
 Midazolam 
Median(IQR) 
Chloral hydrate 
Median(IQR) 
p value 
Time of parental 
Separation (minutes) 0.30(0.15,0.60) 0.20(0.15,0.30) 0.009 
Time of onset of 
sedation (minutes) 0.50(0.23,1.30) 0.25(0.15,0.45) 0.013 
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The results for the above table were computed using Mann-Whitney test and the percentiles 
calculated as above. Children in Midazolam group took 30 minutes and 50 minutes as against 
20 minutes and 25 minutes in chloral hydrate for parental separation and onset of sedation 
respectively. 
2c. Nature of parental separation: 
The nature of parental separation was scored on a scale of 1 to 4. The first 3 were clubbed 
together as one group versus the last score 4 kept as ‗sleepy‘ group. There was no statistically 
significant difference in the nature of parental separation among these children between the 
two groups.  
2d. Time to recovery:   
There was significant difference in the time to recovery with children in the Midazolam 
group showing delayed recovery than their counterparts. The effect of developmental 
maturity on time to recovery was also studied.  
Table 10: 
Time to recovery 
n (%) 
p value 
Normal 
Delayed 
34 (57.14 ) 
26 (42.85 ) 
0.112 
Total sedated 60 (51.21) / 82 
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Fig.8: Kaplan Meyer graph comparing Midazolam (A) with Chloral hydrate (B) among 
developmentally normal children for time of recovery.  
 
Children with normal development who received chloral hydrate recovered earlier than those 
who received Midazolam. 
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Fig.9: Kaplan Meyer graph comparing Midazolam (A) with Chloral hydrate (B) among 
developmentally abnormal children for time of recovery.  
It was also seen that in general, children who were developmentally abnormal required lesser 
time to recover than developmentally normal children as shown in the graph below: 
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Fig.10: Kaplan Meyer graph comparing developmental normal and developmental abnormal 
children for time of recovery.   
But this was not found to be statistically significant. 
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2e. Duration of procedure 
The duration of procedure was almost similar between the two groups.  
 
Table 11 
 
Midazolam 
Mean±SD 
Chloral hydrate 
Mean±SD 
p value 
Duration of 
procedure 0.27±0.07 0.30±0.08 0.210 
 
Time to recovery 
105.95±47.11 78.08±24.11 0.004 
There was no statistically significant difference seen in the total duration the procedure was 
carried once children had attained sedation irrespective of whether they receiver Midazolam 
or Chloral hydrate. 
2f.  Audiologist satisfaction: 
There was a statistically significant difference noted among the audiologist satisfaction. 
There was a 3 scale scoring system with poor /fair / good. The first two were grouped into 
one as ‗not satisfied‘ versus ‗good‘ as satisfied.  
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Table 12: 
Audiologist satisfaction Midazolam 
n (%) 
Chloral hydrate 
n (%) 
 
Satisfied  
Not satisfied  
12 (29.3 ) 
29 (70.7 ) 
31 (75.6 ) 
10 (24.4) 
Total  
41 41 
It was found that audiologists were satisfied overall in 75 % of children who received Chloral 
hydrate as against only 29 % of children who received Midazolam as the remaining children 
either did not sleep or had interrupted movement. 
2f. Parental satisfaction: 
Similarly, 95% of those parents whose children received Chloral hydrate were satisfied 
compared to only 49 % of parents whose children were in the other group. This was found 
statistically significant.   
 Table 13: 
 
Parental satisfaction 
 
Midazolam 
n (%) 
 
Chloral hydrate 
n (%) 
 
p value 
 
Satisfied  
Not satisfied  
 
20 (48.8 ) 
21 (51.2 ) 
 
39 (95.1) 
02 (4.9 ) 
 
 
<0.01 
Total  41 41 
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2g. Number of attempts: 
The number of attempts tried at drug administration was studied.     
 Table 14: 
 
Number of attempts Midazolam 
n (%) 
Chloral hydrate 
n (%) 
 
p value 
 
   1 15 (36.6 ) 33 (80.5) 
 
 
 
<0.01  
   2 26 (76.5 ) 08 (23.5 ) 
 
Total  41 41 
It was found that 26 of 41 children (76.5 %) required a second dose of the drug among the 
Midazolam group while 33 of 41 children (80%) in the Chloral hydrate group slept with only 
a single dosing. It was a statistically significant difference. 
Thus, Chloral hydrate, in our study was found more efficacious in terms of earlier onset of 
sedation and quicker recovery though Midazolam was found equally safe.  
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                                                            Discussion: 
 
With the advent of scientific advancements each day, the numbers of diagnostic tests have 
gone up. Paediatric procedural sedation has become widespread in every field across the 
medical world such that many office procedures are easily carried out without the need for an 
anaesthesiologist.(47,87,88) Auditory Brainstem Response audiometry (ABR) and its 
application in various fields warrant procedural sedation as a routine office procedure. 
Among the various pharmacological agents, Chloral hydrate and Midazolam are known to 
enhance cooperation among children. Adverse effects are known to occur with all classes of 
drugs and with all routes of administration. The once dreaded complications like neurologic 
damage and death, probably due to drug interactions, overdose and administration pathways 
are rarely heard of today. These may be because of the enticing pharmacokinetic properties 
shown by the newer drugs.(89) Many authors have pointed out the guidelines for safe 
sedation.(90)(91) Thus, careful selection of drugs in appropriate patients with vigilant 
monitoring and adequate resuscitation skills have made procedural sedation safe and 
effective.(92)  
NICE guidelines recommend both Chloral hydrate and Midazolam for paediatric painless 
procedural sedation, provided the candidates are assessed thoroughly on an individual basis 
and receive meticulous monitoring with appropriate and adequate resuscitative backup.(93) 
Our study showed both drugs to be safe within the normal therapeutic dosage that was 
administered to achieve adequate sedation for the procedure.  
In this study, we prospectively compared the efficacy and safety of paediatric sedation with 
oral Chloral hydrate and intranasal Midazolam for ABR. Both Chloral hydrate and 
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Midazolam were found to be safe for procedural sedation. However, oral Chloral hydrate is 
more effective than intranasal Midazolam for ABR.  
The safety was measured in terms of the various physiological parameters in both the groups. 
Heart rate, respiratory rate and oxygen saturation were found to be within normal limits safe 
at all intervals, except in one patient in whom Midazolam caused a transient hypoxia, which 
was promptly corrected with appropriate head positioning. There was no need for any 
interventional resuscitative efforts. There were no other major adverse effects seen among 
children in both the groups. A similar result was reported by other studies.(94–97) Rarer 
reported complications like paradoxical reaction, oxygen desaturation, respiratory 
depression, dysrrhythmias and prolonged sedation in varying frequencies have been reported 
by other studies for Chloral hydrate.(98–100) There were no major adverse reactions seen in 
either of the two groups in our study. Studies have shown worrisome adverse effects with 
both the medications in the past. High doses were hypothesized to be responsible for these 
effects even when guidelines and protocols were followed. Cote et al., in 2000 reported 13 of 
20 Chloral hydrate patients and 12 of 26 Midazolam patients had died or sustained permanent 
neurologic injury.(101) Leelataweedwud at al. in 2001 reported, besides 3% of vomiting, 
prolonged sedation, desaturation and apnoea in patients with Chloral hydrate.(102) Martinez 
at al. in 2006 found that children having received combination regimen with Chloral hydrate 
showed prolonged sleepiness compared with those treated with Midazolam.(103) Unlike 
these studies, we did not find any significant differences in the physiological parameters 
between the two groups. This was similar to the study by  Dallman et al. reported in 
2001.(95) 
92 
 
Minor side effects in the Midazolam group were sneezing, hiccups, stinging or burning 
sensation, crying and increased nasal discharge. The incidence of hiccups was found to be 
22% in the study done by Marhofer et al, who showed that the occurrence of hiccups was 
age–dependant, with younger age group more prone. Hiccups were also found to be dose 
independent.(104) In our study, children in the younger age group had hiccups. Sneezing was 
noted among some children similar to Wood et al.(61) Sneezing could be due to the drug 
being used as a spray formulation, which children sometimes find unacceptable. The 
intranasal stinging effect or burning could be due to the effect of the preservative added to 
the intranasal formulation of Midazolam to maintain its stability.(105) It could sometimes be 
perceived as pain, as reported by Antonio et al. who used a score to rate the same.(106) 
Studies have shown that this effect can be ameliorated by adding lignocaine to the same 
formulation or by spraying a separate intranasal lignocaine formulation prior to the 
Midazolam spray.(106–108) In our study, children cried at the time of administering the 
nasal spray, probably due to the atomized aerosol effect or due to the stinging effect in the 
nasal mucosa.(105)(109) Midazolam is also known to cause a bitter taste as it trickles down 
the oropharynx, which has been reported by Isik et al.(110) However, was not seen in our 
study.  Other minor adverse effects reported by various studies like nausea, emesis were not 
shown by children in our study.(111)(112)  
Chloral hydrate, administered at therapeutic doses, has not been reported to cause significant 
adverse effects. Various studies have reported common adverse effects like nausea, vomiting 
with frequencies 3%. (99) In our study, we did not find any of the mentioned side effects. 
Chloral hydrate is a sedative hypnotic with apparent safety and efficacy demonstrated at oral 
doses of 25 to 50 mg/kg, up to 80 to 100 mg/kg with a maximum dose of 1 gm.(113) 
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According to the study done by Malis and Burton, Chloral hydrate is the most frequently 
used sedative for outpatient procedures in children 5 years or younger at an initial minimum 
dose of 61.0 mg/kg.(99)(114) In our study, we sedated children younger than 6 years at an 
initial dose of 50 mg/kg of Chloral hydrate and sedation was achieved in 80% of children 
with the first attempt and overall sedation was achieved in 95% of children.  
Similarly, the safe and effective sedative dose of Midazolam for children from 6 months to 5 
years of age is 0.05 to 0.1 mg/kg to a maximum dose of 0.6 mg/kg titrated gradually to 
achieve adequate sedation in those difficult to sedate children. While for older children 6 to 
12 years of age, the initial dose recommended is 0.025 to 0.05 mg/kg till a maximum of 
0.4mg/kg to achieve the desired sedation.(115) In our study, children were sprayed 
Midazolam at an initial dose of 0.5 mg/kg (100mcg delivered per spray) divided between 
both nostrils and sedation was achieved in 36% of children with the first attempt. Those 
children who required the second dosing received a further half of the initial dosing and 
overall sedation was achieved in 51% of children. 
Chloral hydrate and Midazolam have been recommended for procedural sedation. Studies 
done by Layangool et al., Mc. Carver et al., and Reeves et al., showed an almost equal 
efficacy by both the drugs for sedation.(96,116,117) However, Fallah et al. showed only 40% 
success for sedation with Midazolam as against 76% with oral Chloral hydrate for CT 
imaging.(97)  Similarly, Dallman et al., showed Chloral hydrate to be more effective than 
Midazolam.(95)  In our study, Chloral hydrate was more effective than Midazolam for 
procedural sedation. Sedation was achieved among 95% of children with Chloral hydrate 
when compared to only 51% among the Midazolam group.  
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Following oral administration, Chloral hydrate is rapidly and completely absorbed from the 
gastrointestinal tract and plasma concentration peaks within 30 minutes.(114) Similarly, 
Midazolam administered intranasally has a good absorption rate due to the highly 
vascularized nasal mucosa.(117)(118) Layangool et al., found that intranasal Midazolam has 
a shorter onset of action while Wheeler et al. noted no differences in the onset of sedation 
between both the groups.(119)(120) However, in our study, Chloral hydrate had a faster 
onset of action compared to Midazolam.  
There was no difference in the duration of procedure between the two groups in our study, 
which was similar to the study by D‘Agostino et al. and Reeves et al.(94)(116) Layangool et 
al. showed that though there was no difference in the procedure time between the two groups, 
although the total study time was significantly shorter in the Midazolam group.(119) 
Once sedation was achieved, both the drugs were efficacious in maintaining sleep when the 
procedure was being carried out without any intra-procedural interruption. However, 
Dallman et al. and Layangool et al. showed that patients who received Midazolam slept less 
and had a lesser depth in the level of consciousness than their Chloral hydrate 
counterparts.(95)(119) Laryngool et al. concluded saying the lesser depth in sedation level 
with Midazolam may be advantageous in those high risk patients in whom deep sedation may 
need to be avoided.(119) 
The time taken for parental separation was compared and was found that Chloral hydrate 
helped in earlier parental separation than Midazolam. However, there was no significant 
difference in the nature of parental separation between the two groups. Cote et al. compared 
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three doses of oral Midazolam and showed 88% of satisfactory anxiety rating for parental 
separation.(112)  
Different studies have reported conflicting results in the time to recovery of the sedated 
patients. D‘Agostino et al., Wheeler et al. and Dallman et al. found faster recovery in the 
Midazolam group while Bae et al., and Maeda et al., noted faster recovery in the Chloral 
hydrate group.(94,95,120–122) In our study, children who received Chloral hydrate 
recovered earlier (78 minutes) than the Midazolam group (105 minutes), which was 
significant (p = 0.004). 
Wood et al., in their study using intranasal Midazolam, found that the rating was 8.3 out of 
10 for parental satisfaction.(61) However, in our study, the parental satisfaction was found to 
be better with satisfaction in 95% of children on Chloral hydrate. (p = 0.001). Similarly, 
audiologists were more satisfied with Chloral hydrate group (75%) than when Midazolam 
(29%). 
 In our study, we found that intranasal Midazolam was quite safe and efficacious. When 
compared to Chloral hydrate, it was not superior in ‗time taken for onset of sedation‘ and 
‗time taken for recovery from sedation‘. 
The possible reasons for the comparative lower effectiveness of intranasal Midazolam in our 
study could have been due to the following reasons - some children started crying when the 
drug was sprayed into their nose, even when they were seated on their mother‘s lap. This 
increased nasal secretion, may have diluted the Midazolam spray. Secondly, some children 
sneezed after being sprayed, reducing the efficacy of the medication. Thirdly, older children 
required multiple sprays as the concentration was only 0.5%. This required the children to be 
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restrained for longer periods of time which made them uncooperative. Older children may 
have benefited from higher concentration of Midazolam in the nasal spray. 
Similarly in the Chloral hydrate group, some children spat out the syrup, which might have 
resulted in lesser dose of the drug administered. 
In our study, intranasal Midazolam and oral Chloral hydrate were found to be safe and 
effective for procedural sedation for Auditory Brain Stem Evoked Audiometry. Neither of 
the drugs was found to have any significant side effects. Both parents (95% versus 49%) and 
audiologists (75% versus 29%) were more satisfied with Chloral hydrate than with 
Midazolam. Higher percentage of patients (66%) achieved adequate sedation within the first 
30 minutes with Chloral hydrate than with Midazolam. Both Midazolam and Chloral Hydrate 
are effective in providing sedation for the duration of the procedure. Significant number of 
children achieved sedation with the first attempt of Chloral hydrate than with Midazolam     
(p = 0.01). Successful completion of the procedure with adequate level of sedation was 
achieved in 95% of children with Chloral hydrate, when compared to only 51% among the 
Midazolam group (p <0.01). 
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Conclusion 
In conclusion, Chloral hydrate and Midazolam were both found to be safe. There were no 
major adverse effects noted with either of the drugs. The observed minor side effects were 
not significant.  
Chloral hydrate, when compared to Midazolam, showed a faster onset of sedation and an 
earlier recovery. However, both Chloral hydrate and Midazolam caused adequate sedation 
for the required duration of procedure.  
Parents and audiologists were more satisfied with Chloral hydrate than with Midazolam. 
Significant number of children achieved sedation with the first attempt of Chloral hydrate 
than with Midazolam (p = 0.01).  
Successful completion of the procedure with adequate level of sedation was achieved in 95% 
of children with Chloral hydrate, when compared to only 51% among the Midazolam group 
(p <0.01).  
Overall, both syrup Chloral hydrate and intranasal Midazolam are safe for paediatric 
sedation. However, syrup Choral hydrate was more efficacious than intranasal Midazolam 
for procedural sedation of children undergoing Auditory Brainstem evoked Response 
audiometry.   
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Patient information sheet 
Your child has been referred for a hearing assessment test called Auditory Brainstem evoked 
Response audiometry (ABR). The duration of the procedure is around 45 minutes to one hour 
during which your child is required to be calm and motionless so that the test can be 
performed effectively. As children are playful and especially it is difficult to put hyper 
attentive children to sleep, in our Department, currently, we administer syrup called 
Pedicloryl to make the child sleep. But, not all children sleep with the dose administered and 
sometimes we may have to cancel the procedure as they are not maintained motionless which 
interrupts the completion of the procedure. Again at re-appointments, it is not assured that the 
child sleeps at the first attempt.  
It is for this purpose that a trial is being conducted in our Department. It is to administer a 
drug called Midazolam sprayed through the nose that puts the child to sleep. Midazolam 
belongs to a group of drugs called Sedatives and Hypnotics. It is not a new drug and it has 
been in use since 10 years. It has been found safe among children to cause short term 
sleepiness and faster wake up after the procedure. 
The side effects include sneezing, crying at initial sprays into the nose and hiccups. At times 
children may sleep longer. There may be a remote chance of allergic reactions and airway 
obstruction like any other sedative drug. It is for this purpose that they are monitored 
continuously during the entire procedure by a Doctor till they wake up.  
The trial is conducted in such a way that Midazolam spray is compared with Pedicloryl 
syrup. Your child will receive one of the two drugs to sleep either Midazolam spray or 
Pedicloryl syrup and one other dummy preparation during the trial. Neither you nor your 
Doctor will know which drug is administered to the child. But at any time, your child is 
ensured of one of the drugs to sleep. This is done to compare the effectiveness of both the 
drugs in the best possible way. Otherwise there is no change in the usual performance of the 
procedure.  
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At the completion of the trial if the drug tested, Midazolam is found more effective than 
Pedicloryl, then this may in future help other children referred for ABR. If you are interested 
to know which drug was administered for your child during the procedure, it may be 
intimated to you on request at the end of the entire study period (nearly 15 months). We 
propose to include around 81 patients for the trial. 
To take part in the trial, your child should be from 1 to 6 years of age completed irrespective 
of developmental maturity. Your child should not take part if he / she is allergic to 
Midazolam, if you are not willing for the procedure, if he / she is obese with BMI more than 
30, has nasal allergy or has any other illnesses involving major organs like heart, lungs, liver 
and kidney. 
You are requested to volunteer your child to take part in the trial. Taking part in the trial does 
not incur any extra expenses. If you are not willing your child to take part in the trial, this 
will by no means compromise the usual routine care provided to your child for the procedure. 
The results of the study will be published in a medical journal but your child will not be 
identified by name in any publications or presentation of results. However, his / her medical 
notes may be reviewed by people associated with the study without your additional 
permission, should you decide your child to participate in this study. 
For further queries, you can contact  
Dr. Sharafine Stephen, sharafine@gmail.com 9894542681, Dept. of ENT. 
Dr. John Mathew, jmathew@cmcvellore.ac.in 9994516016, Dept of ENT -2. 
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Informed consent 
I---------------------------------------------------------------------------------------------------------------
mother / father / guardian of -----------------------------------------------------------------------------
declare that I have read the information sheet provided to me regarding this study and have 
clarified any doubts that I had and I also understand that my child‘s participation in this study 
is entirely voluntary and that I am free to withdraw permission to let continue my child to 
participate at any time without affecting his/her usual treatment or legal rights. I also 
understand that neither I, nor my doctors will have any choice or knowledge of which active 
ingredient my child will receive or the identical looking dummy drug. I also understand that 
apart from the cost for the procedure, no extra expenditure will be incurred as part of the trial 
and that my child will receive free treatment for any study related adverse event but will not 
receive any other financial compensation. I understand that the study staff and institutional 
ethics committee members will not need my permission to look at the health records of my 
child. I agree to this access. I understand that the identity of my child will not be revealed in 
any information released to third parties or published. I voluntarily agree to let my child take 
part in this study  
Name: 
Signature: 
Date: 
Name of witness: 
Relation to participant: 
Date: 
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               PEDIATRIC PROCEDURAL SEDATION FORM 
Name                                                                                                  Date   - 
Hospital no.                                                                                        Sample no.  - 
Age   & sex                                                                                        Study arm - 
 Weight                                                                                               Place 
Developmental maturity - normal / abnormal                         
Indication – (Both – 3, speech delay – 2, Hearing impairment – 1) 
Dose calculated - Oral syrup - 50mg/kg =   -- mg      = --- ml 
                              Nasal spray - 0.5 mg/kg = --- mg, ----sprays per nostril (100mcg/spray) 
Parameters  - Pre sedation Baseline 15min  30 min 45min 
Heart rate (bpm)     
Respiratory rate (per min)     
Oxygen saturation (%)     
Level of  
Consciousness 
(scoring) 
Sleep 
(1 to 3) 
    
Movement 
(1 to 4) 
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Parameters – post sedation 
(min) 
5 10  15 20 25 30 35 40 45 50 55 60 65 70 
Heart rate    (bpm)               
Respiratory rate   (per min)               
Oxygen saturation (%)               
Level of  
Consciousness 
(scoring) 
Sleep 
(1 to 3) 
              
Movement 
(1 to 4) 
              
 
Time drugs administered: 
Time for parental separation: 
Nature of parental separation (scoring 1 to 4)  
Time of onset of sedation: 
Duration of procedure --------------- Time started ---------------------; Time ended --------------- 
Time of recovery:  
Nature of recovery (scoring 1 to 4) 
Acceptance by parents:  satisfied / not satisfied 
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Audiologist‘s satisfaction (scoring 1 to 3) 
Number of attempts: 
Rating for parental separation 
Awake   and crying                                                                                    1 
Awake and Calm                                                                                        2 
Drowsy                                                                                                       3 
Sleepy                                                                                                         4 
Houpt Behaviour Rating Scale (modified) 
Level of consciousness                                                                  Score 
Rating for sleep 
Fully awake, alert                                                                                  1 
Drowsy                                                                                                       2 
Asleep                                                                                              3 
Rating for movement 
Violent movement interrupting treatment                                              1 
Continuous movement making treatment difficult                                  2 
Controllable movement that does not interfere with treatment                 3 
No movement                                                                                             4 
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Rating for overall behaviour (by audiologists) 
Poor – procedure aborted                                                                           1 
Fair —procedure interrupted, but completed                                            2 
Good- procedure performed without any interruption                      3 
At recovery,  
Brietkopf and Buttner—Nature of recovery 
Score  Description 
1  Irritated: awake, restless, crying 
2  Normal: awake, calm 
3  Inactive: tired, hardly moving 
4  Sleepy: drowsy, without reaction, but arousable 
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